



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2016

Laboratory tests for diagnosing and monitoring canine leishmaniasis

Paltrinieri, S ; Gradoni, L ; Roura, X ; Zatelli, A ; Zini, Eric

DOI: <https://doi.org/10.1111/vcp.12413>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-128082>

Journal Article

Accepted Version

Originally published at:

Paltrinieri, S; Gradoni, L; Roura, X; Zatelli, A; Zini, Eric (2016). Laboratory tests for diagnosing and monitoring canine leishmaniasis. *Veterinary Clinical Pathology*, 45(4):552-578.

DOI: <https://doi.org/10.1111/vcp.12413>

1 ***LABORATORY TESTS FOR DIAGNOSING AND MONITORING CANINE LEISHMANIASIS***

2

3

4 **Running header: laboratory diagnosis of leishmaniasis**

5

6 Saverio Paltrinieri, DVM, PhD, Dipl ECVCP, Department of Veterinary Sciences and Public

7 Health – University of Milan, Italy

8 Luigi Gradoni, Unit of Vector-borne Diseases & International Health, Department of Infectious

9 Diseases, Istituto Superiore di Sanità, Rome, Italy

10 Xavier Roura, Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain;

11 Andrea Zatelli, Medical Consultancy Services, TàXbiex, Malta

12 Eric Zini, Clinic for Small Animal Internal Medicine, University of Zurich, Switzerland;

13 Department of Animal Medicine, Production and Health, University of Padova, Italy; Istituto

14 Veterinario di Novara, Granozzo con Monticello (NO), Italy.

15

16 Corresponding author:

17 Prof. Saverio Paltrinieri

18 Dipartimento di Scienze Veterinarie e Sanità Pubblica, Università di Milano

19 Via Celoria 10, 20133, Milano, Italy

20 Tel 0039-02-50318103

21 Fax 0039-02-50318095

22 e-mail: saverio.paltrinieri@unimi.it

23

24 **Abstract**

25 Despite several reviews on canine leishmaniasis, none thoroughly described laboratory abnormalities
26 and diagnostic tests in light of their clinical usefulness. Aim was to summarize this information
27 from a practical perspective. Canine leishmaniasis often leads to profound clinicopathological
28 abnormalities. CBC reveals non-regenerative normocytic normochromic anemia and
29 thrombocytopenia, but other types of anemia or leukogram changes are also observed. Clinical
30 chemistry and urinalysis frequently show abnormalities suggestive of renal dysfunction (increased
31 creatinine and urea, decreased urine specific gravity, proteinuria) and inflammatory/immune
32 activation (increased acute phase proteins or α_2 - and/or γ -globulins). The gammopathy is typically
33 polyclonal but can also be oligo- or monoclonal. When lesions accessible to fine needle aspiration
34 or other sampling techniques (lymphadenomegaly, nodular or ulcerated skin lesions, joint
35 swelling) are present, cytology is strongly advised; the disease is confirmed if *Leishmania*
36 amastigotes are identified and pyogranulomatous inflammation or lymphoplasmocytic hyperplasia is
37 present. If results are inconclusive, the parasite should be identified through
38 histology/immunohistochemistry or PCR on surgical biopsies. Alternatively, cytology and PCR
39 may be performed on bone marrow, where amastigotes and erythroid hypoplasia, myeloid
40 hyperplasia, plasmocytosis, or secondary dysmyelopoiesis can be observed. Dogs with overt disease
41 generally have high antibody titers at ELISA or immunofluorescence. Low antibody titers may be
42 found in infected dogs that are immunologically resistant, or in exposed dogs (dogs not harboring
43 the parasite). If leishmaniasis is suspected but cytological evidence of the parasite is negative,
44 serology is recommended for confirmation. In treated dogs, renal function and the magnitude of the
45 inflammatory/immune reaction should be periodically monitored.

46

47

48 ***Keywords: Dog; Leishmania infantum; clinical usefulness; diagnosis; follow-up***

49

51 Leishmaniasis is a frequent infectious disease in dogs living in endemic areas, is associated with
52 important morbidity and, although appropriate treatment, it can cause death. Despite several
53 reviews have been published so far, none has fully described the diagnostic role of laboratory
54 findings that are observed in dogs with leishmaniasis and of available tests. Therefore, the aim of
55 the present review was to provide information concerning laboratory abnormalities and current
56 diagnostic tests, from a practical perspective.

57

58 ***Etiology and pathogenesis of canine leishmaniasis***

59 Canine leishmaniasis is a disease caused by the protozoan parasite *Leishmania infantum*
60 (Kinetoplastida: Trypanosomatidae), or its New World synonym *Leishmania chagasi*.¹ Although
61 non-vectorial transmission is occasionally reported (e.g. by transplacental, transfusional or venereal
62 route),²⁻⁴ it is assumed that canine leishmaniasis is mainly acquired by the bite of infected
63 phlebotomine sand flies (Diptera: Psychodidae). Therefore, the geographical distribution and
64 prevalence of the disease largely depends on the presence and abundance of competent vector
65 species, including members of the *Phlebotomus (Larroussius)* subgenus in the Old World
66 (Mediterranean Basin and Central Asia) and *Lutzomyia longipalpis* and *L. evansi* in the New World
67 (from Mexico through Argentina).⁵ Blood-sucking females ingest the intracellular, non-flagellated
68 form of *Leishmania* (amastigote) during the blood meal on infected hosts. After multiplication,
69 flagellated forms (promastigote) and transform into non-replicative, infectious metacyclic forms
70 that are inoculated into the host's dermis when the fly takes another blood meal. Parasites are
71 phagocytosed by local and recruited host cells, and within phagolysosomes of resident macrophages
72 promastigotes transform and replicate as amastigotes.⁶

73 The pathogenesis of the disease starts with the ingestion of recently inoculated promastigotes by
74 neutrophils that are unable to kill the protozoa but activate dermal macrophages and other
75 mechanisms of innate immunity (e.g. acute phase response). Macrophages initially activate their
76 antimicrobial defenses, which are based on the release of enzymes and on the production of free

77 radicals within the phagolysosome. *Leishmania* organisms are able to interfere with the oxidative
78 activity of the phagocytes^{7,8} and therefore amastigotes can survive and actively replicate in
79 macrophages, leading to cell destruction and infecting progressively more and more phagocytes.
80 In longitudinal field studies employing naïve dogs, it has been demonstrated that *Leishmania* can be
81 detected by PCR in bone marrow samples starting about 6 months from natural exposure to
82 phlebotomine vectors.⁹ Once bone marrow has been colonized it is generally accepted that the dog
83 is persistently infected. However, the same studies showed that dogs being PCR positive in bone
84 marrow may become negative in the following months without any treatment; it is unknown
85 whether the parasite density fluctuates below the threshold limit of the test, the infection persists in
86 organs other than bone marrow, or the host defenses successfully eradicate the infection.⁹ Despite
87 dogs can mount an antibody response after the first contact with the parasites, resistance or
88 susceptibility to progressive infection (leading to clinical disease) depend on the balance between
89 Th1 (cell-mediated) and Th2 (humoral) immune responses of the host: those with prevailing Th2
90 response are more likely to have uncontrolled dissemination of parasites to all body tissues and to
91 show lesions and clinical signs of leishmaniasis.¹⁰⁻¹³

92 Of note, depending on the host-parasite interactions, the simple detection of circulating antibodies
93 does not necessarily imply that the dog is actually infected and detection of parasites in tissues does
94 not suggest that the infected dog is actually sick. Therefore, the two existing guidelines that deal
95 with the diagnosis and staging of canine leishmaniasis, recently released by the Leishvet group¹⁴
96 and the Canine Leishmaniasis Working Group (CLWG),¹⁵ classify dogs as exposed, infected or sick
97 based on a combination of clinical findings and clinicopathological tests or tests for etiological
98 diagnosis. Specifically, both guidelines include two main categories of dogs:

99 - Infected dogs: dogs clinically unremarkable, without abnormalities in hematology, clinical
100 chemistry and urinalysis, that test positive to PCR or cytology in tissues such as bone
101 marrow, lymph node, spleen, skin or peripheral blood;

102 - Sick dogs: infected dogs that have clinical signs or clinicopathological changes consistent
103 with leishmaniasis.

104 The classification of the CLWG¹⁵ includes two additional categories of dogs at the extremes of the
105 spectrum:

106 - Exposed dogs: dogs clinically unremarkable with positive serology, in which PCR or
107 cytology fail to demonstrate the presence of the parasite;

108 - Severely sick dogs: sick dogs that do not respond to treatments and/or are affected by
109 concurrent diseases.

110 The Leishvet group classifies sick dogs in four stages according to the severity of clinical signs and
111 magnitude of antileishmanial antibody titers.¹⁴

112

113 ***Clinical signs of canine leishmaniasis***

114 The interpretation of clinicopathological, serological and molecular tests should be done in light of
115 history, signalment and clinical presentation. History should focus on the risk of exposure to
116 phlebotomine vectors. Signalment should focus on gender, breed and age; clinically overt
117 leishmaniasis is more frequent in male dogs, Boxer and German shepherd, and in those younger
118 than 3 years or older than 8 years,^{16,17} although recent reports suggests that any dog above 2 years
119 is at risk.¹⁸

120 The spectrum of clinical presentations is wide and ranges from infections characterized by the
121 absence of obvious clinical findings but detectable laboratory abnormalities, to overt clinical
122 infections characterized by the presence of clinical and laboratory abnormalities that require or not
123 hospitalization. However, some signs are more frequent than others. The most typical clinical
124 findings include:^{14,15,19-22} generalized lymphadenomegaly, cutaneous lesions, pale mucous
125 membranes, weight loss or cachexia, polyuria/polydipsia, epistaxis, onicogriphosis. Ocular
126 lesions,^{15,23,24} lameness, lethargy and fever are also quite common.^{25,26} In a longitudinal study,²⁷ it
127 was shown that lymph node enlargement appears first (approximately 1 year after exposure to sand

128 flies), followed by cutaneous lesions (after 18 months) and ocular signs (after 22 months).
129 Furthermore, atypical forms have been described, especially in highly endemic areas, including
130 gastrointestinal, neurological, musculoskeletal, cardiopulmonary, lower urinary tract or genital tract
131 signs.²⁸⁻³⁶

132
133 ***Laboratory abnormalities that may support or confirm leishmaniasis***

134 In addition to clinical findings, laboratory abnormalities detectable by routine hematology, clinical
135 chemistry or urinalysis may further increase the clinical suspicion of canine leishmaniasis.
136 Moreover, especially in the early phases of the disease or with atypical presentations, laboratory
137 changes may occur in the absence of obvious abnormalities at physical examination. Therefore, a
138 basic panel is mandatory when canine leishmaniasis is suspected or when a dog with positive result
139 tests for etiological diagnosis needs to be classified as “exposed”, “infected” or “sick”. Table 1
140 summarizes the clinicopathological changes that are found in dogs with leishmaniasis (i.e. “sick”
141 dogs).

142
143 ***1) Hematologic abnormalities***

144 Hematological changes in canine leishmaniasis are non specific.^{37,38} Neutrophilia, due to the
145 systemic inflammatory response associated with the infectious diseases, may be particularly
146 prominent if ulcerative cutaneous lesions with secondary bacterial infection are present.^{37,39,40}
147 Conversely, numerical or morphological changes in the other leukocyte populations are less
148 common, although lymphopenia, lymphocytosis or eosinophilia are occasionally described³⁹⁻⁴²
149 Amastigotes may be rarely documented in circulating leukocytes of infected dogs (0.5% of cases),
150 within neutrophils, lymphocytes and monocytes (figure 1);^{41,43} the percentage of infected cells is so
151 low that their search is generally not rewarding. When a systemic disease and blood dissemination
152 is suspected, more sensitive tests such as PCR or quantitative PCR should be preferred to the simple
153 microscopical examination of blood smears (see below). When parasites are found on smears,

154 however, it is very likely that the parasite burden is high: therefore, although, as stated above, the
155 simple detection of the parasite does not automatically mean that the infected dog is sick, it is more
156 likely that dogs with a high parasite burden (and parasites detected on smears) are sick than simply
157 infected.

158 The most common hematological changes in leishmaniotic dogs is anemia,^{37,38,44,45} that may appear
159 6 months after exposure to infection.²⁷ Anemia is usually mild to moderate and has the normocytic
160 normochromic non regenerative pattern^{40,44,45} typical of the anemia of inflammatory disease, whose
161 pathogenesis include a depression of metabolic activity of bone marrow, in this case sustained also
162 by the infection of stromal cells by the parasite, and a decreased iron availability for
163 erythropoiesis.⁴⁶ However the pathogenesis of anemia in leishmaniotic dogs include additional
164 mechanisms such renal failure leading to reduced erythropoietin synthesis and secondary
165 dismyelopoiesis associated with the production of antibodies against erythroid precursors.⁴⁷
166 Moreover, it is very likely that anemia also has a hemolytic component,⁴⁸ likely due to the presence
167 of anti-RBC antibodies; in a few cases, the hemolysis may be prevalent,⁴⁹ or associated with a
168 “lupus-like” reaction along with other dermatological or systemic signs or laboratory change,
169 including positive ANA-test⁵⁰ or perinuclear antineutrophil cytoplasmic autoantibodies.⁵¹
170 Thrombocytopenia is fairly frequent in leishmaniotic dogs without concurrent infections. It is
171 usually mild to moderate but if severe, co-infections with other vector-borne pathogens (e.g.
172 *Ehrlichia canis*, *Anaplasma phagocytophilum* or *A. platys*) or other possible causes of reduced
173 platelet concentration should be suspected. The most likely mechanism responsible for
174 thrombocytopenia in leishmaniasis is a peripheral consumption of circulating platelets. In turn, this
175 mechanism may be due to immune-mediated mechanisms, since the presence of anti-Plt antibodies
176 has been demonstrated in leishmaniotic dogs.⁵²⁻⁵⁴

177 Moreover, platelet loss may be associated to hypercoagulability caused by a decreased
178 concentration of anti-thrombin III, as in any other protein losing nephropathy⁵⁵ (see below), or to
179 disseminated intravascular coagulation (DIC) that may be occasionally suspected in leishmaniotic

180 dogs.⁵⁶ However, the mechanism of thrombocytopenia in leishmaniotic dogs includes also a
181 decreased production due to the depressed bone marrow activity and to the secondary
182 dysmyelopoiesis cited above. Even in the absence of reduced platelet counts, however, platelet may
183 be hypofunctional in dogs with leishmaniasis⁵⁷ although this reduced function is rarely responsible
184 for hemostatic abnormalities, as described below.

185 One additional hematological test that may be run in dogs with leishmaniasis is the flow-cytometric
186 evaluation of the CD4/CD8 ratio. The rationale for performing this test is that as soon as Th1
187 responses decreases, thus increasing the susceptibility to the disease and favoring the shift from
188 latent infection to overt disease, the number of CD4+ lymphocytes decreases causing reduction of
189 the CD4/CD8 ratio.^{58,59} Therefore, a seropositive or PCR-positive dog with a low CD4/CD8 ratio is
190 more predisposed to develop clinical signs than a similar dog with normal CD4/CD8 ratio. The
191 practical applicability of this test, however, is limited by the high individual variability and by the
192 difficulty to determine a clear cut-off for staging the disease. Hence, this test may be useful for
193 monitoring the post-treatment follow-up, rather than to stage a dog at first diagnosis of
194 leishmaniasis; the authors do not suggest the use of this test for diagnostic purposes in dogs
195 suspected to have leishmaniasis.

196 Finally, the hematological profile of leishmaniotic dogs may be completed by bone marrow
197 cytology.^{27,42,44,60} This analysis may be useful in leishmaniotic dogs to confirm the infection
198 through the detection of infected macrophages, as better specified below, but it may be also used to
199 differentiate a simple infection from systemic disease (i.e. “infected” vs. “sick” dog).¹⁵ Despite
200 some histological studies demonstrated that parasite density can be high despite few clinical signs,⁶¹
201 generally the parasite load and the presence of cytological alterations increase as soon as the dogs
202 show clinical signs.⁶² Therefore, rare infected macrophages may be occasionally seen in the absence
203 of other pathological findings in dogs that are simply infected, whereas dogs in which the parasite
204 induces an inflammatory reaction and/or a systemic disease, are characterized by a higher number
205 of parasites detected cytologically and by a series of morphological changes. Specifically, in the

206 latter case cytology of the bone marrow usually reveals an erythroid hypoplasia,⁴⁰ without
207 abnormalities in the ratio between maturative and proliferative pools of erythroid precursors,
208 occasionally associated with myeloid hyperplasia (and thus with an increased M:E ratio). Moreover,
209 signs of bone marrow inflammation, generically defined by Stockham and Scott as “myelitis”,⁶³ are
210 usually found (figure 2). These include a proliferation of either infected or non-infected
211 macrophages often with signs of erythrophagia or, more generically, cytophagia, associated with an
212 increase of neutrophils in the framework of the myeloid hyperplasia, and a moderate to severe
213 plasmocytosis characterized by a higher number of plasma cells with signs of activation (e.g. mott
214 cells), and lymphocytes.^{64,65} Megakaryocyte hyperplasia may also be present, especially when
215 peripheral consumption of platelets occurs.

216 Secondary dysmyelopoiesis is another common finding, although less frequent than the typical
217 pattern listed above (figure 3). This condition is characterized by multiple peripheral cytopenias
218 (e.g. the anemia and thrombocytopenia cited above) associated with hypercellular bone marrow on
219 which one or more cell lineages show dysplastic features. In canine leishmaniasis, these mostly
220 include dyserythropoiesis and dysmegakariopoiesis, while dysmyelopoiesis (and in particular
221 dysgranulopoiesis, mostly characterized by abnormal maturation and ring forms) is only
222 occasionally found: more specifically, erythroid precursors with abnormal mitoses, asynchronous
223 nucleo-cytoplasmic maturation, nuclear fragmentation, and/or late stage maturation arrest,
224 especially when the pathogenesis includes an immune-mediated reaction against RBC precursors.

225 Dwarf megakaryocytes associated or not with an increased number of megakarioblasts and with
226 emperipolesis may be typical aspects of dysmegakariopoiesis in leishmaniotic dogs. The detection
227 of secondary dysmyelopoiesis however, is not per se diagnostic for leishmaniasis, unless
228 macrophages with intracytoplasmic amastigotes and other signs of reactivity (e.g.
229 lymphoplasmocytic infiltration) are found. Therefore, the cause-effect association between
230 secondary dysmyelopoiesis and the simple seropositivity or PCR-positivity should be carefully
231 considered. Ultimately, in this case the diagnosis of leishmaniasis should be based on the exclusion

232 of other infectious, toxic or metabolic causes of secondary dysmyelopoiesis or of primary
233 myelodysplastic syndromes (MDS) as recommended in hematology textbooks.^{45,47,64}
234 The last and less common finding in bone marrow cytology leishmaniotic dogs may be the presence
235 of erythroid hyperplasia when peripheral signs are consistent with the diagnosis of immune-
236 mediated hemolytic anemia (IMHA). Also in this case, however, IMHA can be associated with
237 leishmaniasis only if the parasite is found in cytological specimens characterized by erythroid
238 hyperplasia. If not, the diagnostic approach should be taken into account only if any other possible
239 cause of IMHA has been excluded. In brief, bone marrow cytology may be useful for diagnostic
240 purposes in some dogs, by detecting amastigotes and compatible cytological abnormalities, or to
241 differentiate between infected dogs from those that are sick due to leishmaniasis.

242

243 2) *Hemostatic abnormalities*

244 Hemostatic abnormalities are uncommon in leishmaniotic dogs. Activated partial thromboplastin
245 time (aPTT) and prothrombin time (PT) may be increased; however, in most cases this is due to
246 preanalytical factors, since their prolongation may occur when the concentration of total globulins
247 increases, which is frequent in dogs with leishmaniasis.⁶⁶ Alternatively, prolonged coagulation
248 times may result from DIC, although this complication is uncommon in leishmaniotic dogs.^{56,67}
249 Conversely, hypercoagulability may be common in leishmaniotic dogs if affected by severe protein
250 losing nephropathy.⁶⁸ This is mostly due to glomerular loss of antithrombin III (ATIII), a protease
251 inhibitor involved in the regulation of blood coagulation that prevents the conversion of fibrinogen
252 into fibrin. The lack of this physiologic anticoagulant may induce hypercoagulability that in turn
253 promotes thrombosis and subsequent consumption coagulopathy. Hypercoagulability is also
254 favored by the hyperviscosity syndrome due to increased circulating globulins.⁶⁹ As in any other
255 hypercoagulable state associated with protein losing nephropathy, hypercoagulability of
256 leishmaniotic dogs was also demonstrated through a decreased clot formation time and an increased
257 global clot strength using thromboelastography (TEG);⁷⁰ differently, in another study the

258 coagulation profile of leishmaniotic dogs assessed by thromboelastometry (TEM, a technique
259 similar to TEG) was within normal limits.⁷¹ However, it is worth noting that TEM and TEG are
260 affected by the RBC mass, possibly explaining the different results obtained with TEM and
261 TEG.^{72,73} In brief, to assess hypercoagulability in dogs with protein losing nephropathy associated
262 with leishmaniasis the authors currently suggest including only ATIII measurement.

263

264 3) *Biochemical abnormalities*

265 Because the clinical presentation of dogs with leishmaniasis is variable, also the type of
266 biochemical abnormalities varies accordingly. Renal dysfunction and inflammation/immune
267 reactions are frequently observed and their presence should be evaluated in each dog with suspected
268 or confirmed leishmaniasis (see below). Regarding other routine biochemical analytes that may be
269 altered in leishmaniotic dogs, there are enzymes of hepatobiliary or pancreatic damage that may
270 increase in case of pyogranulomatous infiltrates affecting these organs,^{15,16} muscular enzymes,
271 including LDH and CK, that may increase with musculoskeletal lesion.⁷⁴ Nevertheless, increased
272 CK may also be due to the increased CK-BB isoenzyme if neurological signs are present,⁷⁵ since
273 *Leishmania* has been found in the brain of some affected dogs with cerebrovascular alterations,⁷⁶⁻⁷⁸
274 or to increased CK-MB if leishmaniotic dogs have cardiomyopathy (i.e. increased troponin I and
275 cardiopulmonary lesions have been reported in many leishmaniotic dogs).⁷⁹⁻⁸¹ Biochemical
276 abnormalities consistent with alteration of endocrine organs are rare, despite amastigotes associated
277 with inflammatory lesions have been found in the adrenal cortex of leishmaniotic dogs.^{82,83}

278

279 *Assessment of renal function*

280 The systemic immune complex disease that characterizes leishmaniasis induces the deposition of
281 circulating immune complexes at the glomerular level. This induces a series of inflammatory
282 glomerular changes detectable histologically and ultramicroscopically,^{36,84,85,86,87} that are primarily
283 responsible for a proteinuric nephropathy.⁸⁷ The evolution of this condition, as for any other

284 protein-losing nephropathy, is represented by the development of a chronic kidney disease (CKD)
285 due to a series of factors that include progressive glomerulosclerosis, renal hypertension, overload
286 of protein reabsorption in tubular cells, with subsequent tubulointerstitial nephritis^{85,87} In turn,
287 advanced stages of CKD are characterized by hyperazotemia and may be associated with systemic
288 hypertension, both factors contributing to comorbidity in dogs with leishmaniasis.^{87,88} Therefore, as
289 for any other renal disease, the early detection of proteinuria and correct classification of CKD is
290 mandatory in the diagnostic workup. To this aim, the clinical and laboratory approach is the same
291 recommended by the International Renal Interest Society (IRIS)⁸⁹ for any type of CKD. This
292 approach is based on a thorough clinical evaluation of the dog, based on physical examination and
293 diagnostic imaging, on the measurement of arterial pressure according to the guidelines
294 recommended by the American College of Veterinary Internal Medicine (ACVIM)⁹⁰ and on the
295 quantification of urinary proteins (described in the section of this article regarding urinalysis) and
296 markers of renal function. According to the IRIS guidelines, these include mostly the urine specific
297 gravity and the serum concentration of creatinine.⁸⁹ This latter has been shown to increase
298 frequently in leishmaniotic dogs^{14,15,16,19,20,91} and early (from 12 to 18 months) following infection.²⁷
299 Creatinine is a good indicator of a decreased glomerular filtration rate (GFR), and it more specific
300 than other markers such as urea^{92,93} but unfortunately they are not enough sensitive to detect the
301 earliest stages of renal insufficiency. Due to the compensatory activity of residual nephrons, in fact,
302 an increase of serum creatinine occur only when the GFR dramatically decreases.⁹³ Therefore,
303 although creatinine is commonly used to detect overt CKD, a huge research activity is currently
304 running in veterinary nephrology and clinical pathology to identify earlier markers of decreased
305 GFR, either in leishmaniotic dogs or in dogs affected by other types of CKD. The direct
306 measurement of GFR trough clearance tests (e.g. clearance of inulin, exogenous creatinine or, more
307 recently, iohexol) would be the best method to assess in real time the functionality of the
308 kidneys^{94,95} Unfortunately these tests, although currently validated for use in dogs, are not widely
309 available in clinical practices or in veterinary laboratories. Therefore, the diagnostic potential of

310 indirect markers other than creatinine has been recently investigated. Cystatin C (Cys C) has been
311 proposed as surrogate marker of creatinine, especially using advanced measurement techniques
312 such as particle-enhanced turbidimetric immunoassay.⁹⁶⁻⁹⁹ The serum concentration of Cys C has
313 been assessed also in dogs with leishmaniasis.¹⁰⁰ However, there is no evidence that serum Cys C,
314 that is less specific than creatinine, is more sensitive than creatinine in detecting early CKD.⁹⁴
315 Promising results have been obtained by the measurement of urinary Cys C¹⁰¹ but this seems not to
316 be true in canine leishmaniasis, where urinary Cys C increases only in proteinuric dogs with
317 increased creatinine.¹⁰² Recently, a promising biomarker for early detection of renal dysfunction
318 seems the symmetric dimethylarginine (SDMA), a catabolite of methylated proteins that is mainly
319 excreted by the glomeruli and not reabsorbed by tubuli,^{103,104} that in published report has been
320 measured in serum using chromatographic techniques.¹⁰⁴ Studies in cats, where the early diagnosis
321 of CKD may be more challenging than in dogs, demonstrated that SDMA increases earlier than
322 creatinine,^{105,106} although it does not provide additional advantages in animals with overt CKD (i.e.
323 with CKD on which serum creatinine is already increased). Preliminary results indicate that SDMA
324 may have the same role of early indicator of renal dysfunction also in dogs,^{104,107} although a few
325 extrarenal variables may affect the results.¹⁰⁸ Therefore, although no studies specifically focused on
326 the use of SDMA in canine leishmaniasis exist, it is very likely that SDMA may be used, in the
327 future, to assess renal function in leishmaniotic dogs that are proteinuric but still have normal
328 creatinine concentration.

329 Other blood markers may provide additional information in leishmaniotic patients with CKD. For
330 example in people the increased serum concentration of homocysteine (Hcy), endothelin-1 (ET-1)
331 or C-reactive protein (CRP) may predict, hypertension and/or inflammation, especially in
332 association with CKD.¹⁰⁹⁻¹¹³ In dogs, Hcy increases in those with CKD¹¹⁴ but seems to be less
333 associated with hypertension than in humans.¹¹⁵ Conversely, ET-1 increases in serum of dogs with
334 hypertension associated with early stages of CKD¹¹⁵ and is also associated with inflammation, as
335 demonstrated by its correlation with CRP levels, which in turn increases mostly in CKD associated

336 with inflammatory conditions.¹¹³ However, the potential of these additional markers as
337 complementary tests for the management of leishmaniotic dogs with CKD has not been
338 investigated. Conversely, inflammatory markers such as CRP, ferritin and adiponectin have been
339 measured in the urine of dogs with leishmaniasis and were found increased in dogs with proteinuria,
340 sometime in the absence of elevated serum creatinine.^{102,116,117} These analytes might therefore work
341 as early markers of CKD in leishmaniotic dogs, although it is more likely that their increase depend
342 on the elevated serum concentration, thus reflecting the inflammatory state typical of leishmaniasis,
343 rather than a direct consequence of CKD.

344 Finally, in leishmaniotic dogs, tubulointerstitial lesions may occur secondarily to proteinuria caused
345 by glomerular damages. Therefore, the availability of markers to identify dogs with tubular lesions
346 would allow to early differentiate dogs with pure glomerular lesions from dogs with more advanced
347 renal damage. Tubular markers, however, are usually measured in urine and not in serum and are
348 described in the section on urinalysis. It is also worth mentioning that some dogs with CKD may
349 have acute deterioration of their renal dysfunction due to factors related or not to leishmaniasis
350 (e.g. vomiting, diarrhea).

351

352 *Assessment of inflammatory/immune reactions*

353 Based on the pathophysiology above described, it is clear that leishmaniotic dogs with overt disease
354 have an intense inflammatory reaction and produces high amount of molecules involved in the
355 immune response, including antibodies. Both these phenomena may be investigated using tests such
356 as protein analysis and serum protein electrophoresis or measurement of acute phase proteins
357 (APPs).

358

359 Protein analysis and serum protein electrophoresis are considered the most accurate tests to
360 diagnose canine leishmaniasis. Protein changes appear 12-18 months after exposure to the
361 parasite.²⁷ Total proteins and total globulin are frequently increased, especially in the acute phase of

362 the disease.^{14,15,16,21,91,118,119} The increase of total protein can correlate with the severity of the
363 clinical score, according to Proverbio et al.¹²⁰ Moreover albumin decreases both because of its role
364 as negative APPs (see below) and of the renal loss associated with proteinuric nephropathy leading
365 to decreased albumin:globulin (A/G) ratio^{91,118,119} The decrease of the A/G ratio is so frequent that it
366 has been considered by some Authors to be one of the more sensitive tests for canine
367 leishmaniasis¹¹⁸ and hypoalbuminemia is considered a negative prognostic factor in leishmaniotic
368 dogs since the magnitude of hypoalbuminemia negatively correlates with survival times.¹²¹ The
369 typical electrophoretogram of leishmaniotic dogs with overt clinical signs (figure 4) displays
370 hypoalbuminemia, an increase of α_2 -globulin, where most of the positive APPs migrate, and
371 especially a strong increase of γ -globulins, due to the huge amount of circulating antibodies,
372 immunocomplexes, and other molecules with γ motility involved in immune-mediated
373 inflammatory reactions.¹¹⁹ Occasionally, peaks due to circulating antibodies are found in the
374 β region, where IgM and some APPs migrates. The gammopathy is typically polyclonal but
375 sometime the peak may be narrower (oligoclonal), biclonal¹²² or definitely monoclonal.¹²³ The
376 interpretation of the peak must take into account the electrophoretic method, since peaks are usually
377 narrower using capillary zonal electrophoresis (CZE) than using agarose gel or cellulose acetate.¹²⁴
378 Therefore, CZE may lead to falsely interpret as monoclonal a peak that is ultimately oligo- or
379 polyclonal (figure 5). Moreover, although monoclonal peaks associated exclusively with
380 leishmaniasis have been described, the detection of monoclonal peaks should induce to consider the
381 possible presence of concurrent diseases (e.g. other vector-borne diseases or multiple
382 myeloma).^{125,126}

383

384 Acute phase proteins are powerful indicators of inflammation: the pro-inflammatory cytokines
385 produced in inflammatory sites induce the so called “acute phase response”, characterized by the
386 release of neutrophils from storage pools, by an activation of myelopoiesis (see above), and by a

387 modulation of protein synthesis in the liver.¹¹⁹ This latter phenomenon leads to a decreased serum
388 concentration of the “negative APPs”, and to an increased concentration of the “positive APPs” that
389 includes a series of immunomodulators, scavenger or transport proteins, antiproteases, and other
390 proteins involved in host defenses.¹¹² Therefore it is not surprising that the serum concentration of
391 positive APPs in dogs with overt canine leishmaniasis is high. The list of APPs whose
392 concentration increases in serum of leishmaniotic dogs is long and includes CRP, Haptoglobin
393 (Hp), Ceruloplasmin (Cp) Serum Amyloid A (SAA) and ferritin,¹²⁷⁻¹³² with CRP and ferritin that, as
394 previously reported, increase also in urine. Similarly, a decrease of negative APPs other than
395 albumin has also been reported; these are transferrin, indirectly measured as total iron binding
396 capacity (TIBC), that induces also a reduction in the concentration of iron, and a decreased activity
397 of the enzyme paraoxonase (PON-1).^{129,130,133} PON-1 is a negative APP that is bound to high
398 density lipoproteins (HDL) and represents a link between inflammation and oxidative stress.
399 Therefore its decrease is not constantly seen in leishmaniotic dogs but it may become evident when
400 oxidative stress is particularly severe.¹³³ Interestingly, in these cases also the concentration of HDL,
401 that is converted into low density lipoprotein (LDL) after detachment of PON-1, decreases¹³⁴ and
402 may be a cheap marker of inflammation and oxidative stress associated with leishmaniasis.
403 Recently a reduced serum activity of adenosine deaminase (ADA) and butyrylcholinesterase
404 (BChE), two enzymes involved in modulating immune responses, has also been reported in dogs
405 with leishmaniasis.¹³⁵
406 The APP changes summarized above are not diagnostic *per se* since mild increases of positive
407 APPs have been reported also in infected dogs without clinical signs¹²⁷ and severely increased
408 levels may occur in diseases other than leishmaniasis.¹¹² In a dog in which leishmaniasis has been
409 diagnosed by other clinical or laboratory findings, however, the magnitude of these changes may
410 reflect the magnitude of inflammation and thus provide prognostic information. In particular, the
411 decrease of PON-1 is particularly evident in severe diseases and may therefore be a negative
412 prognostic marker. Moreover, APPs may be useful to monitor the follow up.

413

414 4) *Abnormalities at urinalysis*

415 The analysis of urine from dogs with suspected or confirmed leishmaniasis must be focused on
416 three main aspects: confirmation of CKD, evaluation of proteinuria, and investigation of possible
417 tubular damage. Urine samples should be analyzed using the usual approach followed in any case of
418 CKD, that starts with the physico-chemical analysis and continues with sediment analysis and
419 evaluation of proteinuria, eventually followed by the measurement of markers of tubular damages.

420

421 *Physico-chemical analysis*

422 According to standardized procedures,¹³⁶ after centrifugation of urine to separate supernatants from
423 the sediment, the routine physicochemical analysis must be addressed to evaluate with a
424 refractometer the urine specific gravity (USG), that tends to decrease in dogs with tubulo-interstitial
425 damage.⁹³ Then, the supernatant can be used for a dipstick analysis, that should be focused on
426 assessing:

- 427 - the pH that, although not extremely accurate¹³⁷ may be useful to properly interpret other
428 dipstick results: for example the semiquantification of proteins may provide erroneously
429 positive results in alkaline urine (pH>8);⁹³
- 430 - the concentration of proteins, to be interpreted as described below;
- 431 - the presence of glucose, that, as specified below, may be an indicator of tubular damage.

432 Sediment analysis is another important step of urinalysis of leishmaniotic dogs: the presence of an
433 active sediment (e.g. a sediment with high numbers of leukocytes, erythrocytes or bacteria) is
434 important either because may indicate a lower urinary tract infection superimposed on the primary
435 disease (leishmaniasis) or because in the presence of an active sediment, results regarding
436 proteinuria should be carefully considered;¹³⁸ conversely, the presence of granular or cellular casts
437 may be consistent with tubular damage.⁹³

438

439 *Evaluation of proteinuria*

440 The evaluation of proteinuria is an essential step, since the presence and magnitude of proteinuria is
441 not only a marker of kidney disease, but also a risk factor for the progression of nephropathy.¹³⁹
442 According to the ACVIM guidelines,¹⁴⁰ proteinuria should be assessed in any dog with diseases
443 potentially inducing this condition, such as leishmaniasis. The ACVIM guidelines recommend to
444 collect urines by cystocentesis, to avoid contamination from the lower urinary tract, however, to
445 improve the possibility to frequently monitor dogs at risk to develop proteinuria, a first evaluation
446 may be done on voided samples, since results recorded with the two methods of collection overlap
447 when the sediment is inactive.¹⁴¹ Additionally, it may be appropriate to screen the possible presence
448 of proteinuria using a dipstick, since it has been demonstrated that if the dipstick is negative or the
449 dogs is likely non proteinuric according to the IRIS classification⁸⁹ and any additional evaluation of
450 proteinuria is therefore not necessary.¹⁴² Conversely, if the dipstick is positive it is very likely that
451 the dog is proteinuric and the protein to creatinine (UPC) ratio must be run to quantify the level of
452 proteinuria. Similarly the UPC ratio must be measured in dogs with a weakly positive dipstick
453 result but with a low USG, in order to understand if the weak positive result really reflect the
454 presence of proteinuria or not.¹⁴² In all the cases above, the UPC ratio must be measured to
455 definitely classify the dog as proteinuric (UPC >0.5), borderline proteinuric (UPC= 0.2-0.5) or non
456 proteinuric (UPC <0.2) according to the IRIS classification, recently revised for the diagnosis of
457 glomerular disease.^{89,143} In the interpretation of data, particular attention should be paid on results
458 close to these threshold since results may be affected by analytical variability or by the type of
459 reagent or laboratory procedures used to measure urinary proteins.¹⁴⁴⁻¹⁴⁶ Then, especially if the dogs
460 is borderline proteinuric or proteinuric, quantification of proteinuria must be repeatedly assessed (at
461 least 3 times in 2 weeks) because, according to the ACVIM guidelines,¹⁴⁰ additional investigations
462 or treatments should be performed only if persistent proteinuria is confirmed by repeated urinalysis.
463 Alternatively, the analysis of proteinuria can be done on pooled urine samples, in order to reduce
464 the possible influence of circadian variations in renal protein excretion.¹⁴⁷ Finally, according to the

465 ACVIM guidelines¹⁴⁰ the origin of urinary protein should be assessed through a renal biopsy.
466 However, according to the recent IRIS guidelines¹⁴³ renal biopsy is recommended only in the case
467 of rapid progression of CKD or in dogs not responding to conventional treatments. Alternatively,
468 the origin of proteinuria can be argued on the basis of surrogate methods such as qualitative analysis
469 of urinary proteins (see below). However, in the case of very high UPC ratio, as usually occur in
470 leishmaniotic dogs, proteinuria is mostly of glomerular origin and tubular proteinuria, if present,
471 contributes only partially to the concentration of urinary proteins.

472

473 *Markers of tubular injury*

474 Although the gold standard method to identify the origin of proteinuria is the histological analysis
475 of renal biopsies, due to its invasiveness this technique is rarely applied in leishmaniotic dogs.
476 However, in order to differentiate the dogs with a tubular component of proteinuria, that are in a
477 more advanced stage of renal disease, urinary markers may be used.¹⁴⁸ Some rough markers such as
478 granular or cellular casts and glycosuria in normoglycemic dogs are very specific indicators of
479 tubular damage, but are not enough sensitive and therefore do not detect dogs with early tubular
480 damage. Additionally, tubular damage so severe to induce glycosuria are rarely observed in
481 leishmaniotic dogs. Early information about the presence of tubular damage may be achieved using
482 sodium dodecylsulphate (SDS) electrophoresis of urinary proteins or measuring the concentration
483 or some urinary analyte or the activity of some urinary enzymes. The SDS denaturates and charges
484 negatively the urinary proteins. Therefore, after migration on polyacrylamide gel (SDS-PAGE) or
485 agarose gel (SDS-AGE), proteins migrate according their molecular mass.¹⁴⁹ This allows to
486 differentiate large proteins, that are of glomerular origin, from small proteins, that are of tubular
487 origin. Results of SDS-PAGE have been shown to well correlate with results of renal biopsies,
488 especially for the identification of glomerular damage or of severe tubule-interstitial damages.¹⁵⁰⁻¹⁵¹
489 while SDS-AGE, that is more diffuse in veterinary laboratories because it may be fully automated
490 and is more rapid, cheap and less toxic than SDS-PAGE.¹⁵¹ However, SDS-AGE has some

491 analytical limitations:¹⁵² it is more susceptible to the concentration of urine thus potentially
492 providing false positive or false negative results in very concentrated or very diluted urine,
493 respectively, and may suffer from pre-analytical artifacts such as bands due to storage artifacts or to
494 proteins originating in the male genital tract.^{153,154} However, using SDS-AGE it has been
495 demonstrated that most of the leishmaniotic dogs have a mixed (glomerular and tubular) pattern and
496 only a minority of dogs, likely those with less “chronic” CKD, have a pure glomerular
497 proteinuria.^{84,155} Occasionally, some leishmaniotic dogs has low molecular weight proteinuria with
498 no signs of glomerular disease, likely due to a free light chain proteinuria (i.e. a pre-renal
499 proteinuria associated with the intense antibody production) rather than to a tubular damage.¹⁵⁶
500 Enzymuria is considered a good marker of tubular damage, since the enzymes of interest are usually
501 located in the cytoplasm of tubular cells. Therefore, they may be found in urine when tubular cells
502 are damaged. Several enzymes may be used for this purpose but the two most popular are γ -
503 glutamyl transferase (GGT) and N-acetyl- β -N-glucosaminidase (NAG)^{93,157} that must be measured
504 just after sampling since their activity decreases after refrigeration or freezing.¹⁵⁸ Increases of these
505 enzymes, as well as of other enzyme such as alkaline phosphatase (ALP) or β -glucuronidase, have
506 been reported in dog with leishmaniasis¹⁵⁹ and the increase of GGT activity has been showed to
507 correlate with the presence of tubular bands in SDS.¹⁵⁵ On the contrary, no information is available
508 on the utility in leishmaniotic dogs of the measurement of other urinary analytes such as clusterin,
509 kidney injury molecule 1 (Kim-1), neutrophil gelatinase-associated lipocalin (NGAL) or retinol
510 binding protein (RBP), used in pharmacology to assess the presence of renal tubular damages and
511 that have been shown to be potentially useful markers in dogs with CKD.^{148,160-162}

512

513 ***Tests for etiological diagnosis that may support or confirm leishmaniasis***

514 Tests for etiological diagnosis are used to identify the presence of the parasite or its components
515 (direct tests) or the host’s response to the parasite (indirect tests). As previously mentioned, positive

516 indirect tests (serology) may or may not indicate a current infection. Conversely, positive direct
517 tests (cytology, histology, immunohistochemistry, PCR, culture and xenodiagnosis) demonstrate
518 that the dog is actually harboring *Leishmania* and it is therefore infected. However, as stated above,
519 the relationship between infection and disease should be based on the evaluation of clinical findings
520 and clinicopathologic tests. The most common tests for etiological diagnosis are described below.

521

522 1) Serology

523 *Methods*

524 Apart from some techniques such as Western blotting, that is highly accurate but not available in
525 routine practice, or other methods that have been proposed but are not extensively used, such as
526 latex agglutination or methods based on the detection of antibodies through immunosensors or flow
527 cytometry,¹⁶³⁻¹⁶⁶ the most common techniques used to detect antibodies are based on three
528 analytical principles: immunofluorescent antibody test (IFAT), enzyme-linked immunosorbent
529 assay (ELISA) and immunochromatographic test (ICT). ICT is the basis of all-rapid “in clinic”
530 assays, which have a major limitation being that they provide results in a qualitative manner (i.e.
531 presence/absence of specific reactive bands).¹⁶⁷ Several commercial ICT kits are available, which
532 employ single or multiple recombinant *Leishmania* antigens to be used on serum, plasma, whole
533 blood or blood spots dried onto filter paper.¹⁶⁸ Several studies have evaluated their diagnostic
534 performances and, in general, they reach similar conclusions: while specificity is quite acceptable,
535 ICT sensitivity is usually low (in the approximate range of 30-70%).¹⁶⁹ Lowest sensitivities are
536 found in infected dogs without clinical signs, the highest ones in those with overt disease.¹⁷⁰
537 Therefore, ICT may be used as a first “in clinic” test to complete the laboratory evaluation of
538 clinically suspected dogs and, in case of positivity, serology should be repeated by ELISA or IFAT,
539 which provide quantitative results (see below). However, due to the low sensitivity of the ICT test,
540 a negative result may be falsely negative and therefore, if the clinical suspicion persists, tests with
541 higher sensitivity (i.e. IFAT or ELISA) should be performed, Recently, a ICT kit claiming detection

542 of antibodies developed after natural infection but not those elicited by vaccination with the LiESP-
543 based vaccine, has been proposed as a tool to differentiate vaccinated from infected dogs.¹⁷¹ The
544 principle of the test is sound, and the first studies reported an elevated sensitivity of this ICT
545 format;¹⁷² however, other studies reported a low sensitivity also for this test.¹⁷³
546 IFAT is recognized as the reference method to perform anti-*Leishmania* serology in dogs,^{169,174} as it
547 is very sensitive and also highly specific except in areas endemic for the New World parasite
548 *Trypanosoma cruzi*, that may give false positive results; values approach 100% for both the
549 parameters. ELISA is also very sensitive and specific when a combination of immunodominant,
550 recombinant proteins are used as antigen, whereas it has slightly lower specificity when crude
551 parasite lysates are employed instead.^{167,173-175} Compared to IFAT, that is based on the evaluation of
552 promastigote fluorescence at UV microscope and is therefore operator-dependent), ELISA is easier
553 to standardize since results are read by an automated spectrophotometer. Both IFAT and ELISA
554 have the advantage to provide quantitative results that are based, respectively, on the final antibody
555 titer (the last sample dilution providing positive result) and optical density values that can be
556 compared with reference titred samples using conversion factors. Based on the unavoidable
557 variability due to operator-dependent or analytical (antigen stability, antiserum or equipment
558 performances) parameters, precise anti-*Leishmania* antibody titers are not universally available.
559 Hence, a titer is considered “high” if it is 4 fold higher than the threshold value of the laboratory.¹⁵
560 Similarly, 4 fold variations in titers of sequential samples of the same dog should be expected in
561 seroconversions, or in the outcome of therapy. Hence, sequential samples must be analyzed by the
562 same method in the same laboratory.

563

564 *Interpretation*

565 Serological tests detect and quantify the presence of antibodies in serum or plasma. Antibodies can
566 be found in blood as soon as 1 month after exposure to infected phlebotomines, although the
567 median time for seroconversion is about 5 months in natural conditions and 3 in experimental

568 studies).¹⁷⁶ Therefore is very likely that dogs living in highly endemic regions seroconvert during
569 the sand fly activity period (from late spring to early autumn in temperate zones, all over the year in
570 tropical ones),⁹ If the infection is efficiently controlled by the host's immune responses, the
571 antibody titers, when present, tend to remain low and therefore these clinically-healthy dogs are
572 classified as exposed or infected.¹⁵ Conversely, the uncontrolled parasite dissemination is associated
573 with an exaggerated humoral response and therefore antibody titers are high when the disease is
574 evident. This condition is classified as "sick dog" or "severely sick dog" by CLWG classification,
575 and stage III or IV (severe or very severe disease) by Leishvet classification.¹⁴ Furthermore, a direct
576 relationship between the clinical score and antibody titers exists.^{120,177} However, dogs with clinical
577 signs (sick) and low-medium antibody titers may also be detected. These have been classified as
578 stage I or II (mild or moderate disease) according to the Leishvet classification.¹⁴
579 Therefore, quantitative serology should always be performed when, despite strong clinical suspicion
580 of leishmaniasis, lesions approachable by fine needle aspiration are not present or when cytological
581 analysis of lesions (including lymphoid organs and bone marrow) does not reveal the typical pattern
582 associated with leishmaniasis, despite a possible PCR positivity. In this case a high antibody titer is
583 often consistent with the disease, while, if the antibody titer is low, leishmaniasis should be
584 considered only if any other disease potentially responsible of the clinical presentation is ruled
585 out.^{14,15}

586

587 2) PCR

588 *Methods*

589 As for serology, several molecular methods have been proposed to detect the presence of the
590 parasite DNA in various biological samples. Some of these methods are not commonly used or
591 recently validated, such as the non-amplification assay based on the use of probes labelled with gold
592 nanoparticles¹⁷⁸ or the loop-mediated isothermal amplification (LAMP).^{179,180} Conversely,
593 conventional PCR, nested PCR and quantitative (real time) PCR are widely used in routine

594 practice.^{14,15,169,174} PCR sensitivity and specificity varies according to the method and especially
595 according to the target DNA sequence. Most of the PCR tests currently used are targeting multicopy
596 DNA sequences, such as the small subunit ribosomal RNA genes or the kinetoplast DNA
597 minicircles, thus increasing the sensitivity of the test.¹⁸¹ Compared with conventional and nested
598 PCR, the quantitative PCR techniques offer two main advantages:¹⁸² they are usually run in close
599 systems and are therefore less prone to contamination, and provide information about the copies of
600 DNA that are present in the sample. This latter aspect may be relevant during the follow up to
601 monitor the efficacy of leishmanicidal treatments and therefore it may advisable to use quantitative
602 PCR at first diagnosis (before any treatment), in order to have a baseline value for further analyses
603 during the follow up^{182,183} However, it does not seem that quantitative PCR techniques are more
604 sensitive than conventional or nested PCR to diagnose leishmaniasis in dogs.¹⁸⁴ One additional
605 limitation of quantitative PCR is that standardized methods to accurately quantify the copies of
606 DNA may not be offered by some laboratories.

607

608 *Samples*

609 PCR techniques may be applied virtually on any tissue or biological fluids. Theoretically, it may be
610 superfluous to use molecular tests in affected tissues in which amastigotes have been visualized by
611 cytology or histology (see below). However, cytology and histology are less sensitive than PCR
612 (see below) and therefore, a negative cytological result does not exclude that amastigotes are
613 present. Therefore, when a fine needle aspirate or a tissue biopsy is performed, it may be advisable
614 to use part of the material to prepare cytological or histological specimens and to store the
615 remaining sample as recommended by the laboratory (usually frozen, fixed in 95% ethyl alcohol or
616 in appropriate preservatives) to run PCR in case amastigotes cannot be visualized despite the
617 cytological or histological pattern is highly consistent with leishmaniasis. If needed, PCR may also
618 be performed on cytological material already fixed on glass slides¹⁸⁵ or on formalin fixed and
619 paraffin embedded material.^{186,187}

620 In routine practice PCR is rarely run on injured tissues, for which cytology and histology are
621 preferred. When lesions are not present, or they are not approachable by fine needle aspiration or
622 biopsy (for example when the prevalent clinical presentation is anemia or proteinuric nephropathy),
623 other samples are preferred. Several studies demonstrated that bone marrow and/or lymph nodes
624 and spleen provide the highest sensitivity in detecting *Leishmania* by PCR, especially in sick
625 dogs,^{14,188-192} pending that the quality of the sample is adequate, especially for the lymph node.
626 Parasite DNA can be easily found in the skin, including intact tissue especially in the facial region
627 or in the ears. Recent studies demonstrated that conjunctival and, to a lesser extent, oral and nasal
628 swab material is very sensitive for the detection of *Leishmania* DNA and, in addition, can provide
629 positive results earlier than other tissues^{188,190,193-196} Buffy coat or whole blood may also be used for
630 conventional or quantitative PCR analysis. Although its sensitivity is lower than that of the other
631 tissues cited above, it can be collected without invasive methods and in the case of positive results
632 provide a diagnostic information in a rapid and cheap way^{14,15}

633

634 *Interpretation*

635 When interpreting PCR results it must be kept in mind the difference between infected and sick
636 dogs. Ultimately, the detection of the parasite's DNA indicates that the dog is infected. The
637 correlation between infection and disease should be based on the presence of clinical signs and
638 laboratory abnormalities. From this perspective, the detection of *Leishmania* DNA in lesions with
639 cytological or histological patterns highly consistent with leishmaniasis (see below) supports the
640 diagnosis of disease and, similarly, a positive PCR in blood or bone marrow of a dog with systemic
641 signs of leishmaniasis can support the diagnosis of disease. Conversely, positive results in dogs
642 without signs clearly referable to leishmaniasis do not support the hypothesis that the infected dog
643 is also affected by clinical leishmaniasis, unless any other possible disease is excluded. For
644 example, a transient PCR-positivity in bone marrow may be found a few months from the natural
645 exposure to sand fly bites, without necessarily meaning that the dogs is infected or sick.⁹ Similarly,

646 the PCR positivity in intact skin of a dog living in an endemic area does not necessarily suggest that
647 the presence of parasites in the skin will be followed by parasite dissemination throughout other
648 body tissues.¹⁰⁻¹³ Skin positive PCR results may in fact be dependent on the presence of recently-
649 inoculated promastigotes, or of amastigotes recently phagocytosed by resident macrophages that, in
650 “resistant” dogs, may efficiently control the infection at local level.^{188,192,197}

651

652 3) Cytology

653 *Samples and methods*

654 Fine needle aspiration should be performed in all cases showing cutaneous papular or nodular
655 lesions and/or lymph node enlargement.¹⁵ Ulcerative cutaneous lesions can be sampled by scraping
656 the lesion or using less invasive methods such as imprint smears. Additionally reports describing
657 the presence of amastigotes and associated lesions in nodular masses with atypical localization,
658 such as the tongue,^{29,33} the testis,¹⁹⁸⁻¹⁹⁹ and oral or nasal masses²⁰⁰ have been reported and therefore
659 any nodular lesion in dogs with clinical or laboratory signs potentially consistent with leishmaniasis
660 (e.g. anemia, CKD, alterations of the electrophoretograms, positive serology) should be sampled by
661 fine needle aspiration. Nasal lesions may also be sampled using brush cytology²⁰¹ Similarly, when
662 clinical or clinicopathological pattern is consistent with leishmaniasis, the possible presence of
663 *Leishmania* should be investigated also in pathological body fluids such as joint fluids,^{25,26}
664 effusions,⁴¹ or cerebrospinal fluid although in this latter sample, cellularity is usually so low that
665 PCR may identify the parasite better than cytology.⁷⁷ In all these cases, fluid samples must be
666 collected by centesis, following the procedures routinely recommended for each site.

667 When cutaneous lesions or nodular lesions in other organs, lymph node enlargement, abnormal
668 accumulation of fluids are absent but the clinical suspicion of leishmaniasis is high, the possible
669 presence of parasites should be investigated in organs rich of cells of the monocyte-macrophage
670 system, such as bone marrow, lymph nodes or spleen^{14,15,60}

671

672 *Interpretation*

673 Cytology aims to demonstrate the presence of amastigotes that are usually found within the
674 macrophages and, when the parasite burden is high and cell lysis occurs, also on the background
675 (figure 6). The detection of amastigotes may be difficult in cutaneous ulcerative lesions, where the
676 presence of necrosis and cellular debris or of contaminating bacteria may mask the presence of
677 amastigotes. Attention should be paid to misinterpret as amastigotes cellular or granular debris that
678 may be present in these lesions.

679 Additionally, cytology may allow to detect the typical inflammatory patterns associated with
680 leishmaniasis, that are usually characterized by pyogranulomatous inflammation associated with a
681 moderate to severe lymphoplasmocytic infiltration in skin or nodular lesions with atypical
682 localization (figure 5) and, in lymph nodes, by a reactive hyperplasia of variable severity,
683 characterized by lymphoplasmocytic and macrophagic infiltration, usually associated with
684 numerous neutrophils.^{60,202,203} Similarly, cytologic patterns typically associated with leishmaniasis
685 may be found in the bone marrow, as described in details in the section dedicated to hematology.
686 Neutrophils, lymphocytes and macrophages can be found also in body fluids of dogs affected by
687 leishmaniasis. Additionally, the fluids may show the features typical of inflammation such as high
688 cell counts and protein contents and, in joint fluids, decreased viscosity and negative mucin clot
689 test.^{25,26,41,77,204,205}

690 The diagnosis of leishmaniasis is easy when amastigotes are detected in samples that shows the
691 cytologic patterns described above. However, when cytologic patterns consistent with leishmaniasis
692 but no amastigotes are seen, leishmaniasis should not be ruled out, since it is known that the
693 diagnostic sensitivity of cytology is low.^{169,174} In these cases, tests that have higher analytical and
694 diagnostic sensitivity, such as PCR, must be run. Alternatively, affected tissues can be biopsied to
695 perform histology and immunohistochemistry, as described below. Conversely, when amastigotes
696 are seen in the absence of cytological abnormalities, or cytology is done on bone marrow, lymph
697 node or spleen, positive results must be interpreted carefully, as systemic signs may be due to

698 diseases other than leishmaniasis.¹⁵ Similarly, a diagnostic workup to confirm or exclude
699 leishmaniasis (i.e. the clinical disease associated with infection) should be run when *Leishmania* is
700 incidentally found in lesions that clearly have a different origin. For example, several reports
701 describe the association between the presence of amastigotes and tumors such as lymphoma,
702 transmissible venereal tumors and other types of neoplasia.²⁰⁶⁻²¹¹ On a practical standpoint in these
703 cases it is important to understand if the dog is affected by both diseases or affected by a neoplastic
704 disease and simply infected with *Leishmania*.

705

706 4) *Histology*

707 Histology can demonstrate the presence of *Leishmania* in routinely hematoxylin and eosin stained
708 sections when cytology provides parasite-negative results in tissues having a cytological pattern
709 highly consistent with leishmaniasis. Compared with PCR, histology has two main disadvantages: it
710 can be more laborious and time consuming, and the identification of amastigotes may be more
711 difficult than in cytological samples. As for the latter, amastigote presence can be confirmed by
712 immunohistochemistry (figure 7),^{36,212} in situ hybridization^{213,214} or PCR on formalin-fixed and
713 paraffin embedded samples.^{186,187} On the other hand, histology has the advantage to provide
714 additional information on the cytoarchitectural pattern of the lesions. This is a great advantage since
715 it may allow to discriminate dogs in which the parasite is associated with typical lesions from those
716 in which the infection does not seem to be associated with the disease. Therefore, according to some
717 guidelines,²² histology should always be performed, especially in the case of cutaneous lesions. The
718 interpretation of histological results is facilitated by the elevated number of papers describing the
719 distribution of parasites and the lesions associated with active disease, mostly characterized by
720 lymphoplasmacytic or granulomatous-pyogranulomatous inflammations and/or by vasculitis either
721 in organs usually affected by *Leishmania* (bone marrow, spleen, skin, lymph nodes, kidney, etc) but
722 also in unusual sites such as heart, lung, adrenal gland, genital tract, central nervous system, skeletal

723 muscle, gastrointestinal tract, nails, lacrimal glands and ocular muscles.^{23,24,29-31,33,36,74,76-78,80-82,84-}
724 86,156,202,215-221

725

726 5) *Parasite culture and biological test for infectiousness (xenodiagnosis)*

727 Conclusive diagnosis of active infection should be based on tissue cultures, which not only confirm
728 whether dogs harbor parasites, but also demonstrate that the protozoa is viable and multiplies
729 actively. A diagnostic *Leishmania* culture, which differs from maintenance culture of laboratory-
730 adapted strains, requires biphasic blood-agar media that need fresh components.⁷⁵ A conclusive test
731 for infectiousness (xenodiagnosis) requires that naive (laboratory-reared) sand flies are induced to
732 feed on infected dogs and are examined thereafter for the presence of promastigotes in the gut.²²²
733 However both tests are unpractical, since on one hand specific blood-agar media are unavailable
734 commercially for diagnostic *Leishmania* culture and must be prepared in laboratory, on the other
735 hand only a few centers breed sand flies for diagnostic purposes. Therefore these tests are mainly
736 intended for research and cannot be recommended for routine practice.

737

738 ***Future perspectives***

739 Several studies investigated the diagnostic potential of innovative markers in dogs with
740 leishmaniasis: for example, the measurement of iron superoxide dismutase (Fe-SODe) secreted by
741 the parasite has been evaluated as a possible marker of infection;²²³ proteomic analysis revealed a
742 series of proteins that are over- or under-represented in leishmaniotic dogs;²²⁴ the analysis of the
743 expression of cytokines or molecules such as leptin or inducible nitric oxide synthetase (iNOS) in
744 blood or tissues revealed different profiles in leishmaniotic dogs compared to controls^{11,13,225-227}
745 high levels of matrix metalloproteinases (MMP), and especially of MMP9 and pro-MMP2, have
746 been reported in serum or CSF of leishmaniotic dogs.^{228,229} However, none of the studies provided,
747 to date, exhaustive information on the possible utility in practice of these markers. However, the

748 information provided in these investigations is useful to design future research and explore their
749 potential clinical application.

750 Similarly, the attention of researchers has been recently focused on markers of oxidative stress;
751 inflammation is characterized by the release of reactive oxygen metabolites from phagocytes
752 recruited in inflammatory sites and this leads to a consumption of antioxidant compounds.²³⁰
753 Increases of oxidants or oxidized molecules (e.g. reactive oxygen metabolites, malonyldialdehyde,
754 lipoperoxides, thiobarbituric acid reacting substances) and decreases of antioxidant compounds
755 (total antioxidant capacity, trace elements, paraoxonase) have been reported in leishmaniotic
756 dogs^{130,133,134,231-234} Unfortunately, only a few studies assessed the diagnostic potential of oxidative
757 markers. for example, the diagnostic performance of ROS were not excellent, likely because
758 oxidative phenomena are intense when inflammation is superimposed to *Leishmania* infection
759 during the clinically overt phase, but depressed if macrophages have been recently infected, due to
760 the ability of the parasite to inhibit the production of oxygen radicals by phagocytes.^{7,8,234}

761

762 ***Tests for monitoring the post-treatment follow up***

763 Laboratory tests during the follow up should be focused in monitoring possible toxic effect of
764 treatment as well as the clinical and the parasitological status of the patient following administration
765 of drugs according to conventional treatments protocols. These mainly include the administration of
766 antimonials and allopurinol or of miltefosine and allopurinol. Treatments different from those listed
767 above should be carefully considered only when conventional treatments are not effective.²³⁵

768

769 ***Monitoring the possible toxic effect of treatment***

770 Theoretically, the possible toxic effects of treatment should be monitored. However, despite some
771 studies reported possible nephrotoxicity of antimonials,^{85,236} others did not confirm this finding,²³⁷
772 and recent investigations demonstrated that no toxic effects on heart or pancreas are induced by
773 these drug category in dogs, differently from what is observed in humans.^{238,239} Therefore, toxic

774 effects should be monitored only in selected dogs, particularly when peculiar clinical findings are
775 present or history might lead to hypothesize any drug adversity. The only possible adverse effect of
776 allopurinol is the formation of xanthine crystals, and possibly urolithes, in urine.²⁴⁰ These occur
777 very frequently and may be sometime abundant although associated clinical signs and urolith
778 formation are less common and suspension of treatment is unusual. Therefore, the analysis of urine
779 sediment should be always included in the laboratory workup when allopurinol is included in the
780 treatment protocol or when urine appears macroscopically turbid or forms an evident pellet after
781 centrifugation (figure 8).

782

783 *Monitoring the clinical status*

784 The clinical presentation of leishmaniotic dogs may be extremely variable. Therefore, it is not
785 possible to define, *a priori*, a common and standardized laboratory work up to be used during the
786 follow up. However, two main aspects need to be monitored each time, namely the presence of
787 renal disease and inflammation.

788 Renal function should be evaluated through the analysis of serum concentrations of creatinine and,
789 especially, through sequential quantification of proteinuria, due to its role as a risk factor for the
790 progression of CKD.¹³⁹ Proteinuria has been recently shown to be a negative prognostic factor in
791 leishmaniotic dogs.¹²¹ After conventional leishmanicidal treatment, the degree of proteinuria
792 decreases in 4-8 weeks,²⁴¹ thus, additional pharmacological treatments for proteinuria should be
793 decided thereafter. The possibility to restore normal renal function depends on the severity of renal
794 damage at the time of first diagnosis. Therefore, creatinine and proteinuria should be repeatedly
795 assessed during the follow up. The frequency of testing depends on the severity of CKD: dogs in
796 IRIS stages 3 or 4⁸⁹ should be frequently tested also during the treatment period. Conversely, dogs
797 in IRIS stages 1 or 2⁸⁹ should be tested at the end of the first treatment cycle and then every 6-12
798 months.²⁴² This latter approach is also recommended by the IRIS Glomerular Disease Study
799 Group,²⁴³ that suggests to evaluate renal functions one month after the end of leishmanicidal

800 treatment, and to decide the frequency of further testing depending on the post-treatment IRIS
801 stage: specifically, tests should be run after 12 months in stage I dogs, every 6 months in dogs in
802 stage 2, every 3 months in dogs in stage 3 and every 6 weeks in dogs in stage 4.

803 The inflammatory status may be monitored through sequential analysis of electrophoretograms and
804 of acute phase proteins, whereas the simple evaluation of total protein, albumin or A/G ratio, may
805 not be helpful because it is very likely that, despite treatment decreases globulin concentrations,
806 albumin concentrations remain low in dogs with persistent glomerular damage and proteinuria, in
807 turn leading to only minor changes in the A/G ratio. Differently, serum protein electrophoresis
808 allow to detect a progressive decrease of α - and γ -globulins. These decreases start to become evident
809 after 2-3 weeks and 4-6 weeks, respectively, following treatment with antimonials.²⁴⁴ Therefore, the
810 first useful electrophoretogram to monitor the efficiency of treatment should be run not earlier than
811 one month after treatment begin.²⁴² The complete normalization of electrophoretograms, however,
812 requires at least 90-120 days.²⁴⁰ If after 2-3 months the electrophoretograms still show abnormal
813 profiles, the possible presence of concurrent diseases such as other vector-borne diseases should be
814 considered, especially if the gammopathy tends to be characterized by narrower peaks (see figure
815 4). Treatments with miltefosine or with other drugs may require longer times to be beneficial (more
816 than 2 months to observe a decrease in γ -globulins) and are also characterized by more frequent of
817 relapses after transient normalization of laboratory profiles.^{245,246} Compared with serum protein
818 electrophoresis, monitoring the concentration of APPs provides earlier information regarding the
819 success of treatments with antimonials. CRP and SAA start to decrease in two weeks after treatment
820 and may return within the reference intervals in about one month.^{131,132,244} The normalization of
821 PON-1 and HDL is even more rapid: significant increases may be observed 3-7 days after treatment
822 and values return within the reference intervals in two weeks.^{112,244} Therefore, to assess the efficacy
823 of treatment, it may be advisable to measure the serum activity of PON-1 or the concentration of
824 HDLs or APPs 1-2 weeks after the first administration of drugs, when other clinical or
825 clinicopathological changes are likely still abnormal.

826

827 *Monitoring the parasitological status*

828 As at first diagnosis, the parasitological status can be monitored indirectly, through the assessment
829 of antibody titers, or by direct evaluation of the parasite presence.

830 In case of successful treatment, a decrease of antibody titers may be expected over time; serology
831 can be repeated during the follow up. However, antibody titers tend to decrease at least 6 month
832 after treatment with antimonials combined with continuous allopurinol administration.²⁴⁰ Hence,
833 serology should not be included in the first laboratory tests performed shortly after treatment to
834 monitor the clinical status. Antibody titers should be determined during subsequent evaluations.²⁴²

835 With regard to serological results, it should be kept in mind that a complete negativization of
836 antileishmanial antibodies is unlikely, especially for dogs living in endemic areas that may be
837 repeatedly exposed to the parasite, boosting the antibody response. Therefore, sequential serological
838 tests during the follow up should aim to assess whether antibody titers decrease to values consistent
839 with the simple exposure (i.e. to less than 4 folds the threshold value of the laboratory).¹⁵

840 In order to assess whether treatment completely eradicates the infection, ideally the presence of
841 parasites should be assessed in the tissues in which the parasite may establish a latent infection and
842 using very sensitive techniques. For this purpose the residual parasites burden should be evaluated
843 with repeated quantitative PCR analyses on bone marrow, spleen or lymph nodes, if still palpable.¹⁵
844 However this procedure is invasive and it is difficult that owners accept the analysis, especially if
845 treatment has been successful and the dog is clinically healthy. Therefore, in routine practice the
846 evaluation of treatment efficacy is usually assessed with serology or quantitative PCR analysis in
847 blood. If treatment is successful, the latter test may show a clear decrease of the *Leishmania* DNA
848 copies after 3 to 6 months of therapy, with complete negativization occurring between 6 and 12
849 months.¹⁸²

850

851 *Conclusive remarks and recommended protocols*

852 Diagnosing leishmaniasis in dogs may be difficult due to the complex pathogenesis and broad
853 spectrum of clinical and clinicopathological findings. Hence tests that need to be included in the
854 diagnostic protocol vary in each case or epidemiological scenario.²⁴⁷

855 In clinically healthy dogs living or having travelled to an endemic area serology may be the test of
856 choice to assess any possible exposure to parasites. Based on the median time to achieve
857 seroconversion,¹⁷⁶ serology should be performed at least 6 months after exposure, or periodically
858 (e.g. every 6 months-1 year) in dogs living in endemic areas. If serology is positive, it is important
859 to quantify the antibody response: a low antibody titer may be consistent with exposure or an early
860 phase of infection, while a high antibody titer may suggest infection or disease.^{14,15} Therefore, the
861 subsequent diagnostic steps should confirm the suspected infection through cytological and PCR
862 analysis of sensitive tissues, and/or identification of possible clinical or laboratory alterations,
863 especially in dogs with high antibody titers. If serology or PCR is positive and tests have been
864 performed beyond the transmission season, the laboratory workup should identify the most common
865 abnormalities of dogs with leishmaniasis but no clinical sign (e.g. anemia, abnormal serum protein
866 electrophoresis, proteinuria). If changes are detected, additional clinical or laboratory tests must be
867 performed in order to stage the disease (e.g. tests recommended by the IRIS guidelines for CKD,⁸⁹
868 tests to quantify the acute phase response of inflammation).

869 If the dog is examined because clinical abnormalities are evident, the veterinarian should try to
870 sample any accessible lesion to obtain cytological smears.¹⁵ If amastigotes are documented and the
871 cytological pattern is consistent with leishmaniasis the dog is considered sick; thus, next diagnostic
872 steps should clarify whether a systemic involvement is also present (e.g. hematological disorder,
873 inflammation, nephropathy) and quantify the antibody titer or parasite burden with quantitative
874 PCR to obtain baseline values useful during treatment follow-up. Conversely, if amastigotes are not
875 observed but cytological patterns are consistent with leishmaniasis, the lesion can be further
876 analyzed by histology combined with immunohistochemistry, in situ hybridization or PCR.^{14,15} A
877 positive result with one of these additional tests should lead to investigate further the general health

878 status of the sick dog; conversely, if tests are negative, the presence of infection should be assessed
879 in the bone marrow through cytology and/or PCR and, in case of positive results, further
880 clinopathological tests should be performed as above.^{14,15} Regarding serology, its use is advisable
881 to confirm the disease in dogs suspected to have leishmaniasis but yielding no parasites at
882 cytological examination. Higher titers are more likely to occur in dogs with leishmaniasis and a
883 more severe clinical presentation.

884

885 **Conflict of interest statement**

886 The authors are members of the Canine Leishmaniasis Working Group (CLWG). None of
887 the authors of this paper has a financial or personal relationship with other people or organisations
888 that could inappropriately influence or bias the content of the paper.

889

890 **Acknowledgements:**

891 The authors are grateful to Dr. Alessia Giordano for the collaboration in revising the manuscript.

892

893 **References**

- 894 1. Kuhls K, Alam MZ, Cupolillo E, Ferreira GE, et al. Comparative microsatellite typing of
895 New World *Leishmania infantum* reveals low heterogeneity among populations and its
896 recent Old World origin. *PLoS Negl Trop Dis*. 2011;5:e1155.
- 897 2. Rosypal AC, Troy GC, Zajac AM, Frank G, Lindsay DS. Transplacental transmission of a
898 North American isolate of *Leishmania infantum* in an experimentally infected beagle. *J*
899 *Parasitol*. 200;91:970-972.
- 900 3. De Freitas E, Melo MN, da Costa-Val AP, Michalick MSM. Transmission of *Leishmania*
901 *infantum* via blood transfusion in dogs: potential for infection and importance of clinical
902 factors. *Vet Parasitol*. 2006;137:159-167.

- 903 4. Silva FL, Oliveira RG, Silva TM, Xavier MN, Nascimento EF, Santos RL. Venereal
904 transmission of canine visceral leishmaniasis. *Vet Parasitol.* 2009;160:55-59.
- 905 5. Maroli M, Feliciangeli MD, Bichaud L, Charrel RN, Gradoni L. Phlebotomine sandflies and
906 the spreading of leishmaniasis and other diseases of public health concern. *Med Vet*
907 *Entomol.* 2013;27:123-147.
- 908 6. Bates PA. Transmission of *Leishmania* metacyclic promastigotes by phlebotomine sand
909 flies. *Int J Parasitol.* 2007;37:1097-1106.
- 910 7. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to *Leishmania*
911 *major* in mice. *Nat Rev Immunol.* 2002;2:845–858;
- 912 8. Engwerda CR, Ato M, Kaye PM. Macrophages, pathology and parasite persistence in
913 experimental visceral leishmaniasis. *Trends Parasitol.* 2004;20:524–530.
- 914 9. Oliva G, Scalone A, Foglia Manzillo V, et al. Incidence and time course of *Leishmania*
915 *infantum* infections examined by parasitological, serologic, and nested-PCR techniques in a
916 cohort of naive dogs exposed to three consecutive transmission seasons. *J Clin Microbiol.*
917 2006;44:1318-1322.
- 918 10. Pinelli E, Killick-Kendrick R, Wagenaar J, Bernadina W, del Real G, Ruitenber J. Cellular
919 and humoral immune responses in dogs experimentally and naturally infected with
920 *Leishmania infantum*. *Infect Immun.* 1994;62:229-235.
- 921 11. Santos-Gomes GM, Rosa R, Leandro C, Cortes S, Romão P, Silveira H. Cytokine
922 expression during the outcome of canine experimental infection by *Leishmania infantum*.
923 *Vet Immunol Immunopathol.* 2002;88:21-30.
- 924 12. Brachelente C, Muller N, Doherr MG, Sattler U, Welle M. Cutaneous leishmaniasis in
925 naturally infected dogs is associated with a T helper-2-biased immune response. *Vet Pathol.*
926 200;42:166-175.
- 927 13. Chamizo C, Moreno J, Alvar J. Semi-quantitative analysis of cytokine expression in
928 asymptomatic canine leishmaniasis. *Vet Immunol Immunopathol.* 2005;103:67-75.

- 929 14. Solano-Gallego L, Koutinas A, Miró G, et al. Directions for the diagnosis, clinical staging,
930 treatment and prevention of canine leishmaniosis. *Vet Parasitol.* 2009;165:1-18.
- 931 15. Paltrinieri S, Solano-Gallego L, Fondati A, et al. Guidelines for diagnosis and clinical
932 classification of leishmaniasis in dogs. *J Am Vet Med Assoc.* 2010;236:1184-1191.
- 933 16. Alvar J, Canavate C, Molina R, Moreno J, Nieto J. Canine leishmaniasis. *Adv Parasitol.*
934 2004;57:1-88.
- 935 17. Fisa R, Gallego M, Castillejo S, et al. Epidemiology of canine leishmaniosis in Catalonia
936 (Spain) the example of the Priorat focus. *Vet Parasitol.* 1999;83:87-97.
- 937 18. Cortes S, Vaz Y, Neves R, Maia C, Cardoso L, Campino L. Risk factors for canine
938 leishmaniasis in an endemic Mediterranean region. *Vet Parasitol.* 2012;189:189-96.
- 939 19. Slappendel RJ: Canine leishmaniasis. A review based on 95 cases in The Netherlands. *Vet*
940 *Q.* 1988;10:1-16.
- 941 20. Ciaramella P, Oliva G, Luna RD, et al. A retrospective clinical study of canine leishmaniasis
942 in 150 dogs naturally infected by *Leishmania infantum*. *Vet Rec.* 1997;141:539-543.
- 943 21. Koutinas AF, Polizopoulou ZS, Saridomichelakis MN, Argyriadis D, Fytianou A, Plevraki
944 KG. Clinical consideration on canine leishmaniasis in Greece: a retrospective study of 158
945 cases (1989-1996). *J Am Anim Hosp Assoc.* 1999;35:376-383.
- 946 22. Noli C, Saridomichelakis MN. An update on the diagnosis and treatment of canine
947 leishmaniosis caused by *Leishmania infantum* (syn. *L. chagasi*). *Vet J.* 2014;202:425-435.
- 948 23. Naranjo C, Fondevila D, Leiva M, Roura X, Peña T. Detection of *Leishmania spp.* and
949 associated inflammation in ocular-associated smooth and striated muscles in dogs with
950 patent leishmaniosis. *Vet Ophthalmol.* 2010;13:139-143.
- 951 24. Peña MT, Naranjo C, Klauss G, et al. Histopathological features of ocular leishmaniosis in
952 the dog. *J Comp Pathol.* 2008;138:32-39.
- 953 25. Sbrana S, Marchetti V, Mancianti F, Guidi G, Bennett D. Retrospective study of 14 cases of
954 canine arthritis secondary to *Leishmania* infection. *J Small Anim Pract.* 2014;55:309-13.

- 955 26. Santos M, Marcos R, Assuncao M, Matos AJ. Polyarthritis associated with visceral
956 leishmaniasis in a juvenile dog, *Vet Parasitol.* 2006;141:340-344.
- 957 27. Foglia Manzillo V, Di Muccio T, Cappiello S, et al. Prospective study on the incidence and
958 progression of clinical signs in naïve dogs naturally infected by *Leishmania infantum*. *PLoS*
959 *Negl Trop Dis.* 2013;;7:e2225.
- 960 28. Adamama-Moraitou KK, Rallis TS, Koytinas AF, Tontis D, Plevraki K, Kritsepi M.
961 Asymptomatic colitis in naturally infected dogs with *Leishmania infantum*: a prospective
962 study. *Am J Trop Med Hyg.* 2007;76:53-57.
- 963 29. Parpaglia ML, Vercelli A, Cocco R, Zobba R, Manunta ML. Nodular lesions of the tongue
964 in canine leishmaniosis. *J Vet Med A Physiol Pathol Clin Med.* 2007;54:414-417.
- 965 30. Silva FL, Rodrigues AA, Rego IO, et al. Genital lesions and distribution of amastigotes in
966 bitches naturally infected with *Leishmania chagasi*. *Vet Parasitol.* 2008;151:86-90.
- 967 31. Silva JF, Guimarães LB, Ribeiro LR, Moreira MV, Serakides R, Ocarino NM. Acute
968 oesophageal necrosis concurrent with *Leishmania chagasi* infection in a dog. *J Comp*
969 *Pathol.* 2014;;150:148-150.
- 970 32. Blavier A, Keroack S, Denerolle P, et al. Atypical forms of canine leishmaniosis. *Vet J.*
971 2001;162:108-120.
- 972 33. Viegas C, Requicha J, Albuquerque C, et al. Tongue nodules in canine leishmaniosis--a case
973 report. *Parasit Vectors.* 2012;5:120.
- 974 34. Mir F, Fontaine E, Reyes-Gomez E, Carlus M, Fontbonne A. Subclinical leishmaniasis
975 associated with infertility and chronic prostatitis in a dog. *J Small Anim Pract.* 2012;53:419-
976 422.
- 977 35. Ruiz G, Laloy E, Benchekroun G. Chronic gastritis and enterocolitis associated with
978 *Leishmania* infection in an 18-month-old, intact female dog. *Vet Q.* 2015; June 8:1-4 [Epub
979 ahead of print].

- 980 36. dos Santos JP, Alves LC, Ramos RA, et al. Histological changes and immunolabeling of
981 *Leishmania infantum* in kidneys and urinary bladder of dogs. *Rev Bras Parasitol Vet.*
982 2013;22:420-423.
- 983 37. Groulade P . Canine leishmaniasis. Clinical haematology and biology of leishmaniasis .
984 *Anim Compagn* 1977;12:121-128.
- 985 38. Kiral, FK , Seyrek, K, Pasa, S, Ertabaklar, H, Unsal, C. Some haematological, biochemical
986 and electrophoretic findings in dogs with visceral leishmaniasis. *Revue Med Vet.*
987 2004;155:226-229.
- 988 39. Schultze AE. Interpretation of Canine Leukocyte Response. In: Weiss DJ, Wardrop KY, eds.
989 *Schalm's Veterinary Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:321-324
- 990 40. Nicolato R de C, de Abreu RT, Roatt MB et al. Clinical forms of canine visceral
991 Leishmaniasis in naturally *Leishmania infantum*-infected dogs and related myelogram and
992 hemogram changes. *PLoS One*. 2013;8:e82947.
- 993 41. Ruiz de Gopegui, R, Espada Y. Peripheral Blood and Abdominal Fluid from a Dog with
994 Abdominal Distention. *Vet Clin Pathol*. 1998;27:64-67.
- 995 42. De Tommasi AS, Otranto D, Furlanello T, et al. Evaluation of blood and bone marrow in
996 selected canine vector-borne diseases. *Parasit Vectors*. 2014;7:534
- 997 43. Giudice E, Passantino A Detection of *Leishmania* amastigotes in peripheral blood from four
998 dogs. *Acta Vet Hung*. 2011;59:205-13.
- 999 44. Gavazza A , Lubas G , Gugliucci B , Pasquini A, Mancianti F. Hemogram and bone marrow
1000 patterns in canine leishmaniasis. *Vet Clin Pathol*. 2002;31:198.
- 1001 45. Wardrop KJ, Infectious injury to bone marrow In: Weiss DJ, Wardrop KY, eds. *Schalm's*
1002 *Veterinary Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:118-120.
- 1003 46. Fry MM. Anemia of nflammatory, neoplastic, renal, and endocrine diseases In: Weiss DJ,
1004 Wardrop KY, eds. *Schalm's Veterinary Hematology*, 6th ed. Ames, IA: Wiley-Blackwell;
1005 2010:246-250.

- 1006 47. Weiss DJ. Myelodysplastic syndromes In: Weiss DJ, Wardrop KY, eds. *Schalm's Veterinary*
1007 *Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:467-474.
- 1008 48. Day MJ. Immune - mediated anemias in the dog In: Weiss DJ, Wardrop KY, eds. *Schalm's*
1009 *Veterinary Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:216-225
- 1010 49. Tvedten H. Laboratory and clinical diagnosis of anemia In: Weiss DJ, Wardrop KY, eds.
1011 *Schalm's Veterinary Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:152-161.
- 1012 50. Smith BE, Tompkins MB, Breitschwerdt EB. Antinuclear antibodies can be detected in dog
1013 sera reactive to *Bartonella vinsonii subsp. berkhoffii*, *Ehrlichia canis*, or *Leishmania*
1014 *infantum* antigens. *J Vet Intern Med.* 2004;18:47-51.
- 1015 51. Karagianni AE, Solano-Gallego L, Breitschwerdt EB, et al. Perinuclear antineutrophil
1016 cytoplasmic autoantibodies in dogs infected with various vector-borne pathogens and in
1017 dogs with immune-mediated hemolytic anemia. *Am J Vet Res.* 2012;73:1403-1409.
- 1018 52. Terrazzano G, Cortese L, Piantedosi D, et al. Presence of anti - platelet IgM and IgG
1019 antibodies in dogs naturally infected by *Leishmania infantum*. *Vet Immunol Immunopathol.*
1020 2006;110:331-337.
- 1021 53. Cortese L, Sica M, Piantedosi D, et al.: Secondary immune-mediated thrombocytopenia in
1022 dogs naturally infected by *Leishmania infantum*. *Vet Rec.* 2009;164:778-782.
- 1023 54. Cortese L, Terrazzano G, Piantedosi D, et al. Prevalence of anti-platelet antibodies in dogs
1024 naturally co-infected by *Leishmania infantum* and *Ehrlichia canis*. *Vet J.* 2011;188:118-21.
- 1025 55. Green RA, Kabal AL. Hypercoagulable state in three dogs with nephrotic syndrome: role of
1026 acquired antithrombin III deficiency. *J Am Vet Med Assoc.* 1982;181:914-917.
- 1027 56. Honse CO, Figueiredo FB, de Alencar NX, Madeira M de F, Gremião ID, Schubach TM.
1028 Disseminated intravascular coagulation in a dog naturally infected by *Leishmania*
1029 (*Leishmania*) *chagasi* from Rio de Janeiro - Brazil. *BMC Vet Res.* 2013;9:43.
- 1030 57. Abid M, Kalbantner K, Mischke R. Platelet function in dogs with bacterial infections and
1031 leishmaniasis. *Berl Munch Tierarztl Wochenschr.* 2015;128:289-296.

- 1032 58. Papadogiannakis E, Andritsos G, Kontos V, Spanakos G, Koutis C, Velonakis E.
1033 Determination of CD4+ and CD8+ T cells in the peripheral blood of dogs with
1034 leishmaniosis before and after prolonged allopurinol monotherapy. *Vet J.* 2010;186:262-
1035 263.
- 1036 59. Rosypal AC, Gogal RM Jr, Zajac AM, Troy GC, Lindsay DS. Flow cytometric analysis of
1037 cellular immune responses in dogs experimentally infected with a North American isolate of
1038 *Leishmania infantum*. *Vet Parasitol.* 2005;131:45-51.
- 1039 60. Saridomichelakis MN, Mylonakis ME, Leontides LS, Koutinas AF, Billinis C, Kontos VI.
1040 Evaluation of lymph node and bone marrow cytology in the diagnosis of canine
1041 leishmaniasis (*Leishmania infantum*) in symptomatic and asymptomatic dogs. *Am J Trop*
1042 *Med Hyg.* 2005;73:82-86.
- 1043 61. Momo C, Jacintho AP, Moreira PR, Munari DP, Machado GF, Vasconcelos Rde O.
1044 Morphological changes in the bone marrow of the dogs with visceral leishmaniasis. *Vet Med*
1045 *Int.* 2014;2014:150582.
- 1046 62. Trópia de Abreu R, Carvalho Md, Carneiro CM, et al. Influence of clinical status and
1047 parasite load on erythropoiesis and leucopoiesis in dogs naturally infected with *leishmania*
1048 (*Leishmania*) *chagasi*. *PLoS One.* 2011;6:e18873.
- 1049 63. Stockham SL, Scott MA. Bone marrow and lymph node. In: Stockham SL, Scott MA, eds.
1050 *Fundamentals of veterinary clinical pathology*, 2nd ed. Ames, IA: Blackwell Publishing;
1051 2008:323-368.
- 1052 64. Weiss DJ . Chronic Inflammation and secondary myelofibrosis In: Weiss DJ, Wardrop KY,
1053 eds. *Schalm's Veterinary Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:112-117
- 1054 65. Foglia Manzillo V , Restucci B , Pagano A , Gradoni L, Oliva G. Pathological changes in
1055 the bone marrow of dogs with leishmaniasis. *Vet Rec.* 2006;158:690-694.

- 1056 66. Lubas G., Caldin M., Wiinberg B., Kristensen A.M. Laboratory testing of coagulation
1057 disorders In: Weiss DJ, Wardrop KY, eds. *Schalm's Veterinary Hematology*, 6th ed. Ames,
1058 IA: Wiley-Blackwell; 2010:1082-1100.
- 1059 67. Okano S, Yoshida M, Fukushima U, Higuchi S, Takase K, Hagio M. Usefulness of systemic
1060 inflammatory response syndrome criteria as an index for prognosis judgement. *Vet Rec*.
1061 2002;150:245-246.
- 1062 68. Braun JP, Lefevbre, HP. Kidney function and damage. In: Kaneko JJ, Harvey JW, Bruss
1063 ML.eds. *Clinical Biochemistry of Domestic Animals*, 6th ed. San Diego, CA: Elsevier;
1064 2008:457-528.
- 1065 69. Borgatti A. Plasma cell tumors In: Weiss DJ, Wardrop KY, eds. *Schalm's Veterinary*
1066 *Hematology*, 6th ed. Ames, IA: Wiley-Blackwell; 2010:511-519
- 1067 70. Lennon EM, Hanel RM, Walker JM, Vaden SL. Hypercoagulability in dogs with protein-
1068 losing nephropathy as assessed by thromboelastography. *J Vet Intern Med*. 2013;27:462-
1069 468.
- 1070 71. Bruno B, Maurella C, Falco S, et al. Thromboelastometric evaluation of hemostasis in dogs
1071 infected with *Leishmania infantum*. *J Vet Emerg Crit Care (San Antonio)*. 2015;25:502-511.
- 1072 72. Brooks AC, Guillaumin J, Cooper ES, Couto CG. Effects of hematocrit and red blood cell-
1073 independent viscosity on canine thromboelastographic tracings. *Transfusion*. 2014;54:727-
1074 734.
- 1075 73. McMichael MA, Smith SA, Galligan A, Swanson KS. In vitro hypercoagulability on whole
1076 blood thromboelastometry associated with in vivo reduction of circulating red cell mass in
1077 dogs. *Vet Clin Pathol*. 2014;43:154-163.
- 1078 74. Vamvakidis CD1, Koutinas AF, Kanakoudis G, Georgiadis G, Saridomichelakis M.
1079 Masticatory and skeletal muscle myositis in canine leishmaniasis (*Leishmania infantum*).
1080 *Vet Rec*. 2000;146:698-703.

- 1081 75. Paltrinieri S., Cazzaniga S., Pinto da Cunha N., Giordano A. Electrophoretic fractionation of
1082 creatine kinase isoenzymes and macroenzymes in clinically healthy dogs and cats and
1083 preliminary evaluation in central neurologic diseases. *Vet Clin Pathol.* 2010;39:329-333.
- 1084 76. Grano FG, Melo GD, Belinchón-Lorenzo S, Gómez-Nieto LC, Machado GF. First detection
1085 of *Leishmania infantum* DNA within the brain of naturally infected dogs. *Vet Parasitol.*
1086 2014;204:376-380.
- 1087 77. Márquez M1, Pedregosa JR, López J, Marco-Salazar P, Fondevila D, Pumarola M.
1088 *Leishmania* amastigotes in the central nervous system of a naturally infected dog. *J Vet*
1089 *Diagn Invest.* 2013;25:142-146.
- 1090 78. José-López R1, la Fuente CD, Añor S. Presumed brain infarctions in two dogs with systemic
1091 leishmaniasis. *J Small Anim Pract.* 2012;53:554-557.
- 1092 79. Silvestrini P, Piviani M, Alberola J, et al. Serum cardiac troponin I concentrations in dogs
1093 with leishmaniasis: correlation with age and clinicopathologic abnormalities. *Vet Clin*
1094 *Pathol.* 2012;41:568–574.
- 1095 80. Rosa FA1, Leite JH, Braga ET, et al. Cardiac lesions in 30 dogs naturally infected with
1096 *Leishmania infantum chagasi*. *Vet Pathol.* 2014;51:603-606.
- 1097 81. Alves GB, Pinho FA, Silva SM, Cruz MS, Costa FA. Cardiac and pulmonary alterations in
1098 symptomatic and asymptomatic dogs infected naturally with *Leishmania (Leishmania)*
1099 *chagasi*. *Braz J Med Biol Res.* 2010;43:310-315.
- 1100 82. Momo C, Rocha NA, Moreira PR, et al. Morphological changes and parasite load of the
1101 adrenal from dogs with visceral leishmaniasis. *Rev Bras Parasitol Vet.* 2014;23:30-35.
- 1102 83. Saridomichelakis MN, Xenoulis PG, Chatzis MK, et al. Thyroid function in 36 dogs with
1103 leishmaniosis due to *Leishmania infantum* before and during treatment with allopurinol with
1104 or without meglumine antimonate. *Vet Parasitol.* 2013;197:22-28.
- 1105 84. Zatelli A, Borgarelli M, Santilli R, et al. Glomerular lesions in dogs infected with
1106 *Leishmania* organisms. *Am J Vet Res.* 2003;64:558-561.

- 1107 85. Aresu L, Benali S, Ferro S, et al. Light and electron microscopic analysis of consecutive
1108 renal biopsy specimens from *Leishmania*-seropositive dogs. *Vet Pathol.* 2013;50:753-760.
- 1109 86. Rigo RS, Carvalho CM, Honer MR, et al. Renal histopathological findings in dogs with
1110 visceral leishmaniasis. *Rev Inst Med Trop Sao Paulo.* 2013;55:113-116.
- 1111 87. Koutinas AF, Koutinas CK. Pathologic mechanisms underlying the clinical findings in
1112 canine leishmaniasis due to *Leishmania infantum/chagasi*. *Vet Pathol.* 2014;51:527-538.
- 1113 88. Braga ET, Leite JH, Rosa FA, et al. Hypertension and its correlation with renal lesions in
1114 dogs with leishmaniosis. *Rev Bras Parasitol Vet.* 2015;24:45-51.
- 1115 89. International renal Interest Society (IRIS): Guidelines for staging chronic kidney disease
1116 (CKD). Available at: www.iris-kidney.com. Accessed, October 20, 2015
- 1117 90. Brown S, Atkins C, Bagley R, et al. Guidelines for the identification, evaluation, and
1118 management of systemic hypertension in dogs and cats. *J Vet Intern Med.* 2007;21:542-558.
- 1119 91. Ribeiro RR, da Silva SM, Fulgêncio Gde O, Michalick MS, Frézard FJ. Relationship
1120 between clinical and pathological signs and severity of canine leishmaniasis. *Rev Bras*
1121 *Parasitol Vet.* 2013;22:373-378.
- 1122 92. Braun JP, Lefebvre HP, Watson AD. Creatinine in the dog: a review. *Vet Clin Pathol.*
1123 2003;32:162-179.
- 1124 93. Stockham SL, Scott MA. Urinary system. In: Stockham SL, Scott MA, eds. *Fundamentals*
1125 *of veterinary clinical pathology*, 2nd ed. Ames, IA: Blackwell Publishing; 2008:415-494.
- 1126 94. Von Hendy-Willson VE, Pressler BM. An overview of glomerular filtration rate testing in
1127 dogs and cats. *Vet J.* 2011;188:156-165.
- 1128 95. Sasaki Y, Iwama R, Shimamura S, et al. Estimation of glomerular filtration rate in dogs by a
1129 single-blood sample method involving iodixanol. *Am J Vet Res.* 2015;76:828-835.
- 1130 96. Jensen AL, Bomholt M, Moe L. Preliminary evaluation of a particle-enhanced turbidimetric
1131 immunoassay (PETIA) for the determination of serum cystatin C-like immunoreactivity in
1132 dogs. *Vet Clin Pathol.* 2001;30:86-90

- 1133 97. Almy FS, Christopher MM, King DP, Brown SA . Evaluation of cystatin C as an
1134 endogenous marker of glomerular filtration rate in dogs. *J Vet Intern Med.* 2002;16:45-51.
- 1135 98. Miyagawa Y, Takemura N, Hirose H. Evaluation of the measurement of serum cystatin C by
1136 an enzyme-linked immunosorbent assay for humans as a marker of the glomerular filtration
1137 rate in dogs. *J Vet Med Sci.* 2009;71:1169-1176.
- 1138 99. Ghys L, Paepe D, Smets P, Lefebvre H, Delanghe J, Daminet S. Cystatin C: a new renal
1139 marker and its potential use in small animal medicine. *J Vet Intern Med.* 2014;28:1152-
1140 1164.
- 1141 100. Pasa S, Bayramli G, Atasoy A, Karul A, Ertug S, Ozensoy Toz S. Evaluation of
1142 serum cystatin-C in dogs with visceral leishmaniasis. *Vet Res Commun.* 2009;33:529-534.
- 1143 101. Monti P, Benchekroun G, Berlato D, Archer J. Initial evaluation of canine urinary
1144 cystatin C as a marker of renal tubular function. *J Small Anim Pract.* 2012;53:254-259.
- 1145 102. García-Martínez JD, Martínez-Subiela S, Tvarijonaviciute A, Caldin M, Ceron JJ.
1146 Urinary ferritin and cystatin C concentrations at different stages of kidney disease in
1147 leishmaniotic dogs. *Res Vet Sci.* 2015;99:204-207.
- 1148 103. Jepson RE, Syme HM, Vallance C, Elliott J., Plasma asymmetric dimethylarginine,
1149 symmetric dimethylarginine, l-arginine, and nitrite/nitrate concentrations in cats with
1150 chronic kidney disease and hypertension. *J Vet Intern Med.* 2008;22:317-324.
- 1151 104. Nabity MB, Lees GE, Boggess MM, et al. Symmetric Dimethylarginine Assay
1152 Validation, Stability, and Evaluation as a Marker for the Early Detection of Chronic Kidney
1153 Disease in Dogs. *J Vet Intern Med.* 2015;29:1036-1044.
- 1154 105. Braff J, Obare E, Yerramilli M, Elliott J, Yerramilli M. Relationship between serum
1155 symmetric dimethylarginine concentration and glomerular filtration rate in cats. *J Vet Intern
1156 Med.* 2014;28:1699-1701.
- 1157 106. Hall JA, Yerramilli M, Obare E, Yerramilli M, Yu S, Jewell DE. Comparison of
1158 serum concentrations of symmetric dimethylarginine and creatinine as kidney function

- 1159 biomarkers in healthy geriatric cats fed reduced protein foods enriched with fish oil, L-
1160 carnitine, and medium-chain triglycerides. *Vet J.* 2014;202:588-596.
- 1161 107. Yerramilli M, Yerramilli M, Obare E, Jewell DE, Hall JA. Symmetric
1162 dimethylarginine (SDMA) increases earlier than serum creatinine in dogs with chronic
1163 kidney disease (CKD). *J Vet Intern Med.* 2014;28:1084–1085.
- 1164 108. Hall JA, Yerramilli M, Obare E, Yerramilli M, Melendez LD, Jewell DE.
1165 Relationship between lean body mass and serum renal biomarkers in healthy dogs. *J Vet*
1166 *Intern Med.* 2015;29:808-814.
- 1167 109. Stanger, O., Herrmann, W., Pietrzik, K., et al. DACH-LIGA Homocystein (German,
1168 Austrian and Swiss Homocysteine Society): Consensus paper on the rational clinical use of
1169 homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases:
1170 Guidelines and recommendations. *Clin Chem Lab Med.* 2003;41:1392-1403.
- 1171 110. Schiffrin EL. Role of endothelin-1 in hypertension. *J Am Heart Assoc.* 1999;34:876-
1172 881.
- 1173 111. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. *Can J*
1174 *Physiol Pharmacol.* 2008;86:485-498.
- 1175 112. Ceron JJ, Eckersall PD, Martinez-Subiela S. Acute phase proteins in dogs and cats:
1176 Current knowledge and future perspectives. *Vet Clin Pathol.* 2005;34:85-99.
- 1177 113. Raila J, Schweigert FJ, Kohn B. C-reactive protein concentrations in serum of dogs
1178 with naturally occurring renal disease. *J Vet Diagn Invest.* 2011;23:710-715.
- 1179 114. Rossi S, Rossi G, Giordano A, Paltrinieri S. Homocysteine measurement by an
1180 enzymatic method and potential role of homocysteine as a biomarker in dogs. *J Vet Diagn*
1181 *Invest.* 2008;20:644-649.
- 1182 115. Rossi G, Giordano A, Breda S, et al. Big-endothelin 1 (Big ET-1) and homocysteine
1183 in the serum of dogs with chronic kidney disease. *Vet J.* 2013;198:109-115.

- 1184 116. Martínez-Subiela S, García-Martínez JD, Tvarijonaviciute A, et al. Urinary C
1185 reactive protein levels in dogs with leishmaniasis at different stages of renal damage. *Res*
1186 *Vet Sci.* 2013;95:924-929.
- 1187 117. Tvarijonaviciute A, Ceron JJ, Martinez-Subiela S, García-Martínez JD. Serum and
1188 urinary adiponectin in dogs with renal disease from leishmaniasis. *Vet Rec.* 2012;171:297.
- 1189 118. Almeida MA, Jesus EE, Sousa-Atta ML, Alves LC, Berne ME, Atta AM. Clinical
1190 and serological aspects of visceral leishmaniasis in northeast Brazilian dogs naturally
1191 infected with *Leishmania chagasi*. *Vet Parasitol.* 2005;127:227-232.
- 1192 119. Eckersall PD. Proteins, proteomics, and the dysproteinemias. In: Kaneko JJ, Harvey
1193 JW, Bruss ML. eds. *Clinical Biochemistry of Domestic Animals*, 6th ed. San Diego, CA:
1194 Elsevier; 2008:117-156
- 1195 120. Proverbio D, Spada E, Bagnagatti de Giorgi G, Perego R, Valena E. Relationship
1196 between *Leishmania* IFAT titer and clinicopathological manifestations (clinical score) in
1197 dogs. *Biomed Res Int.* 2014;2014:412808.
- 1198 121. Geisweid K, Mueller R, Sauter-Louis C, Hartmann K. Prognostic analytes in dogs
1199 with *Leishmania infantum* infection living in a non-endemic area. *Vet Rec.* 2012;171:399.
- 1200 122. Vailati Facchini R, Bertazzolo W, Zuliani D, et al. Detection of biclonal
1201 gammopathy by capillary zone electrophoresis in a cat and a dog with plasma cell neoplasia.
1202 *Vet Clin Pathol.* 2010;39:440-446.
- 1203 123. Font A, Closa JM, Mascort J. Monoclonal gammopathy in a dog with visceral
1204 leishmaniasis. *J Vet Int Med.* 1994;8:233-235.
- 1205 124. Giordano A, Paltrinieri S. Interpretation of capillary zone electrophoresis compared
1206 with cellulose acetate and agarose gel electrophoresis: reference intervals and diagnostic
1207 efficiency in dogs and cats. *Vet Clin Pathol.* 2010;39:464-473.

- 1208 125. Antognoni MT, Biretoni F, Miglio A, Lalli P, Porciello F, Mangili Pecci V.
1209 Monoclonal gammopathy associated with multiple myeloma and visceral leishmaniasis in
1210 the dog: a comparison of two cases. *Vet Res Commun.* 2010;34 Suppl 1:S97-101.
- 1211 126. Geigy C, Riond B, Bley CR, Grest P, Kircher P, Lutz H. Multiple myeloma in a dog
1212 with multiple concurrent infectious diseases and persistent polyclonal gammopathy. *Vet Clin*
1213 *Pathol.* 2013;42:47-54.
- 1214 127. Martínez-Subiela S, Tecles F, Eckersall PD, Cerón JJ. Serum concentrations of acute
1215 phase proteins in dogs with leishmaniasis. *Vet Rec.* 2002;150:241-244.
- 1216 128. Martinez-Subiela S, Strauss-Ayali D, Cerón JJ, Baneth G. Acute phase protein
1217 response in experimental canine leishmaniasis. *Vet Parasitol.* 2011;180:197-202.
- 1218 129. Silvestrini P, Zoia A, Planellas M, et al. Iron status and C-reactive protein in canine
1219 leishmaniasis. *J Small Anim Pract.* 2014;55:95-101.
- 1220 130. Martinez-Subiela S, Cerón JJ, Strauss-Ayali D, et al. Serum ferritin and paraoxonase-
1221 1 in canine leishmaniosis. *Comp Immunol Microbiol Infect Dis.* 2014;37:23-29.
- 1222 131. Martínez-Subiela S, Bernal LJ, Cerón JJ. Serum concentrations of acute-phase
1223 proteins in dogs with leishmaniosis during short-term treatment. *Am J Vet Res.*
1224 2003;64:1021-1026.
- 1225 132. Sasanelli M, Paradies P, de Caprariis D, et al. Acute-phase proteins in dogs naturally
1226 infected with *Leishmania infantum* during and after long-term therapy with allopurinol. *Vet*
1227 *Res Commun.* 2007;31 Suppl 1:335-338.
- 1228 133. Rossi G, Giordano A, Pezzia F, Kjelgaard-Hansen M, Paltrinieri S. Serum
1229 paraoxonase activity (PON1) in dogs: preanalytical and analytical factors and correlation
1230 with C-reactive protein and alpha-2-globulin. *Vet Clin Pathol.* 2013;42:329-341.
- 1231 134. Ibba F, Rossi G, Meazzi S, Giordano A, Paltrinieri S. Serum concentration of high
1232 density lipoproteins (HDLs) in leishmaniotic dogs. *Res Vet Sci.* 2015;98:89-91.

- 1233 135. Tonin AA, Calado AM, Bottari NB, et al. Novel markers of inflammatory response
1234 and hepatic dysfunction in canine leishmaniasis. *Comp Immunol Microbiol Infect Dis*. 2015
1235 pii: S0147-9571(15)00064-8. doi: 10.1016/j.cimid.2015.09.004. [Epub ahead of print]
- 1236 136. Osborne CA, Stevens J. Urine sediment. In: Osborne CA, Stevens J. *Urinalysis: a*
1237 *clinical guide to compassionate patient care*. Shawnee, KS; Bayer Corporation: 1999;125-
1238 150.
- 1239 137. Heuter KJ, Buffington CA, Chew DJ. Agreement between two methods for
1240 measuring urine pH in cats and dogs. *J Am Vet Med Assoc*. 1998;213:996-998.
- 1241 138. Vaden SL, Pressler BM, Lappin MR, Jensen WA. Effects of urinary tract
1242 inflammation and sample blood contamination on urine albumin and total protein
1243 concentrations in canine urine samples. *Vet Clin Pathol*. 2004;33:14-19.
- 1244 139. Jacob F, Polzin DJ, Osborne CA, et al. Evaluation of the association between initial
1245 proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal
1246 failure. *J Am Vet Med Assoc*. 2005;226:393-400.
- 1247 140. Lees GE, Brown SA, Elliott J, Grauer GE, Vaden SL; American College of
1248 Veterinary Internal Medicine. Assessment and management of proteinuria in dogs and cats:
1249 2004 ACVIM Forum Consensus Statement (small animal). *J Vet Intern Med*. 2005;19:377-
1250 385.
- 1251 141. Beatrice L, Nizi F, Callegari D, et al. Comparison of urine protein-to-creatinine ratio
1252 in urine samples collected by cystocentesis versus free catch in dogs. *J Am Vet Med Assoc*.
1253 2010;236:1221-1224.
- 1254 142. Zatelli A, Paltrineiri S, Nizi F, Roura X, Zini E. Evaluation of a urine dipstick test for
1255 confirmation or exclusion of proteinuria in dogs. *Am J Vet Res*. 2010;71:235-240.
- 1256 143. IRIS Canine GN Study Group Diagnosis Subgroup, Littman MP, Daminet S, Grauer
1257 GF, Lees GE, van Dongen AM. Consensus recommendations for the diagnostic

- 1258 investigation of dogs with suspected glomerular disease. *J Vet Intern Med.* 2013;;27 Suppl
1259 1:S19-526.
- 1260 144. Rossi G, Giori L, Campagnola S, Zatelli A, Zini E, Paltrinieri S. Evaluation of
1261 factors that affect analytic variability of urine protein-to-creatinine ratio determination in
1262 dogs. *Am J Vet Res.* 2012;73:779-788.
- 1263 145. Rossi G, Bertazzolo W, Dondi F, et al. Inter-laboratory variability in
1264 protein:creatinine (UPC) ratio on canine urine. *Vet J.* 2015;204:66-72.
- 1265 146. Rossi G, Bertazzolo W, Binnella M, Scarpa P, Paltrinieri S. Measurement of
1266 proteinuria in dogs: analytical and diagnostic differences using two laboratory methods *Vet*
1267 *Clin Pathol.* In press
- 1268 147. LeVine DN, Zhang D, Harris T, Vaden SL. The use of pooled vs serial urine samples
1269 to measure urine protein:creatinine ratios. *Vet Clin Pathol.* 2010;39:53-56.
- 1270 148. Smets PM, Meyer E, Maddens BE, Duchateau L, Daminet S. Urinary markers in
1271 healthy young and aged dogs and dogs with chronic kidney disease. *J Vet Intern Med.*
1272 2010;24:65-72.
- 1273 149. Schultze,AE, Jensen RK. Sodium dodecyl sulfate polyacrylamide gel electrophoresis
1274 of canine urinary proteins for the analysis and differentiation of tubular and glomerular
1275 diseases. *Vet Clin Pathol.* 1998;18:93-97.
- 1276 150. Brown JS, Nabity MB, Brock R, Cianciolo R, Lees GE. Comparison of urine sodium
1277 dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with renal histological
1278 findings and clinicopathologic data in dogs with renal diseases. *Vet Clin Pathol.*
1279 2010;39:556.
- 1280 151. Zini E, Bonfanti U, Zatelli A. Diagnostic relevance of qualitative proteinuria
1281 evaluated by use of sodium dodecyl sulfate-agarose renal histologic findings in dogs. *Am J*
1282 *Vet Res.* 2004;65:964-971.

- 1283 152. Giori L, Tricomi FM, Zatelli A, Roura X, Paltrinieri S. High-resolution gel
1284 electrophoresis and sodium dodecyl sulphate–agarose gel electrophoresis on urine samples
1285 for qualitative analysis of proteinuria in dogs. *J Vet Diagn Invest.* 2011;23:682-690.
- 1286 153. Nadaud C, Piane L, Theron ML, Palanche F, Trumel C, Lavoue R. 2014. Urine
1287 electrophoretic protein profile of healthy male dogs. *Vet Clin Pathol.* 2005;44:E8–E9
- 1288 154. Theron ML, Trumel C, Piane L, Lucarelli L, Henrion R, Lavoue R. Effects of storage
1289 conditions on canine urine sodium dodecyl sulfate-agarose gel electrophoresis (SDS-AGE).
1290 *Vet Clin Pathol.* 2013;42:34.
- 1291 155. Ibba F, Mangiagalli G, Paltrinieri S. Urinary gamma-glutamyl transferase (GGT) as a
1292 marker of tubular damage in dogs with canine leishmaniasis, using sodium dodecylsulphate
1293 (SDS) electrophoresis as a reference method. *Vet J. in press*
- 1294 156. Bonfanti U, Zini E, Minetti E, Zatelli A. Free light-chain proteinuria and normal
1295 renal histopathology and function in 11 dogs exposed to *Leishmania infantum*, *Ehrlichia*
1296 *canis*, and *Babesia canis*. *J Vet Intern Med.* 2004;18:618-624.
- 1297 157. Bruncker JD, Ponzio NM, Payton ME. Indices of urine N-acetyl-beta-D-
1298 glucosaminidase and gamma-glutamyl transpeptidase activities in clinically normal adult
1299 dogs. *Am J Vet Res.* 2009;70:297-301.
- 1300 158. Matteucci E, Giampietro O. To store urinary enzymes: how and how long? *Kidney*
1301 *Int. Suppl.* 1994;47:S58-559.
- 1302 159. Palacio J, Liste F, Gascón M. Enzymuria as an index of renal damage in canine
1303 leishmaniasis. *Vet Rec.* 1997;140:477-480.
- 1304 160. García-Martínez JD, Tvarijonaviciute A, Cerón JJ, Caldin M, Martínez-Subiela S.
1305 Urinary clusterin as a renal marker in dogs. *J Vet Diagn Invest.* 2012;24:301-306.
- 1306 161. Nability MB, Lees GE, Cianciolo R, Boggess MM, Steiner JM, Suchodolski JS.
1307 Urinary biomarkers of renal disease in dogs with X-linked hereditary nephropathy. *J Vet*
1308 *Intern Med.* 2012;26:282-293.

- 1309 162. Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity-
1310 an overview for applied toxicology. *AAPS J.* 2011;13:615-631.
- 1311 163. Sousa S, Cardoso L, Reed SG, et al. Development of a fluorescent based
1312 immunosensor for the serodiagnosis of canine leishmaniasis combining immunomagnetic
1313 separation and flow cytometry. *PLoS Negl Trop Dis.* 2013;7:e2371.
- 1314 164. Ker HG, Coura-Vital W, Aguiar-Soares RD, et al. Evaluation of a prototype flow
1315 cytometry test for serodiagnosis of canine visceral leishmaniasis. *Clin Vaccine Immunol.*
1316 2013;20:1792-1798.
- 1317 165. Ramos-Jesus J, Carvalho KA, Fonseca RA, et al. A piezoelectric immunosensor for
1318 *Leishmania chagasi* antibodies in canine serum. *Anal Bioanal Chem.* 2011;401:917-925.
- 1319 166. Akhoundi B, Mohebali M, Shojaee S, et al. Rapid detection of human and canine
1320 visceral leishmaniasis: assessment of a latex agglutination test based on the A2 antigen from
1321 amastigote forms of *Leishmania infantum*. *Exp Parasitol.* 2013;133:307-313.
- 1322 167. Maia C, Campino L. Methods for diagnosis of canine leishmaniasis and immune
1323 response to infection. *Vet Parasitol.* 2008;158:274-287.
- 1324 168. Rosypal AC, Pick LD, Hernandez JO, Lindsay DS. Evaluation of a novel dried blood
1325 spot collection device (HemaSpot™) to test blood samples collected from dogs for
1326 antibodies to *Leishmania infantum*. *Vet Parasitol.* 2014;205:338-342.
- 1327 169. EFSA AHAW Panel (EFSA Panel on Animal Health and Welfare), 2015. Scientific
1328 Opinion on canine leishmaniosis. *EFSA Journal* 2015;13:4075, 77 pp.
1329 doi:10.2903/j.efsa.2015.4075
- 1330 170. Grimaldi G Jr, Teva A, Ferreira AL, et al. Evaluation of a novel chromatographic
1331 immunoassay based on Dual-Path Platform technology (DPP® CVL rapid test) for the
1332 serodiagnosis of canine visceral leishmaniasis. *Trans R Soc Trop Med Hyg.* 2012;106:54-59.
- 1333 171. Sagols E, Martin V, Claret E, McGahie D, Ciusinier AM, Gueguen S. Evaluation of
1334 the humoral immune response after vaccination with LiESP/QA21 (CaniLeish): interest of

- 1335 *Leishmania* specific anti-kinesin antibodies detection. *Proceedings of the 2012 BSAVA*
1336 *Congress*, Birmingham, United Kingdom, April 12th-15th, 2012
- 1337 172. Ferroglio E, Zanet S, Mignone W, Poggi M, Trisciuglio A, Bianciardi P. Evaluation
1338 of a rapid device for serological diagnosis of *Leishmania infantum* infection in dogs as an
1339 alternative to immunofluorescence assay and Western blotting. *Clin Vaccine Immunol.*
1340 2013;20:657-659.
- 1341 173. Solano-Gallego L, Villanueva-Saz S, Carbonell M, Trotta M, Furlanello T, Natale
1342 Aserological diagnosis of canine leishmaniosis: comparison of three commercial ELISA
1343 tests (Leiscan, ID Screen and *Leishmania* 96), a rapid test (Speed Leish K) and an in-house
1344 IFAT. . *Parasit Vectors.* 2014;7:111.
- 1345 174. Gradoni L, Gramiccia M. Leishmaniosis. In *Manual of diagnostic tests and vaccines*
1346 *for terrestrial animals.* World Organisation for Animal Health (OIE); 2008:240-250. (2014
1347 update available at:
1348 [http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.01.08_LEISHMANIOSIS.](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.01.08_LEISHMANIOSIS.pdf)
1349 [pdf](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.01.08_LEISHMANIOSIS.pdf); accessed, October 20, 2015)
- 1350 175. Rodríguez-Cortés A, Ojeda A, Francino O, López-Fuertes L, Timón M, Alberola J.
1351 *Leishmania* infection: laboratory diagnosing in the absence of a "gold standard". *Am J Trop*
1352 *Med Hyg.* 2010;82:251-256.
- 1353 176. Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental
1354 model. *Trends Parasitol.* 2002;18:399-405.
- 1355 177. dos-Santos WL, Jesus EE, Paranhos-Silva M, et al. Associations among
1356 immunological, parasitological and clinical parameters in canine visceral leishmaniasis:
1357 emaciation, spleen parasitism, specific antibodies and leishmanin skin test reaction. *Vet*
1358 *Immunol Immunopathol.* 2008;5:3-4.

- 1359 178. Andreadou M, Liandris E, Gazouli M, et al. A novel non-amplification assay for the
1360 detection of *Leishmania spp.* in clinical samples using gold nanoparticles. *J Microbiol*
1361 *Methods*. 2014;96:56-61.
- 1362 179. Chaouch M, Mhadhbi M, Adams ER, et al. Development and evaluation of a loop-
1363 mediated isothermal amplification assay for rapid detection of *Leishmania infantum* in
1364 canine leishmaniasis based on cysteine protease B genes. *Vet Parasitol*. 2013;198:78-84.
- 1365 180. Gao CH, Ding D, Wang JY, et al. Development of a LAMP assay for detection of
1366 *Leishmania infantum* infection in dogs using conjunctival swab samples. *Parasit Vectors*.
1367 2015;8:370.
- 1368 181. Cortes S, Rolao N, Ramada J, Campino L. PCR as a rapid and sensitive tool in the
1369 diagnosis of human and canine leishmaniasis using *Leishmania donovani* s.l.-specific
1370 kinetoplastid primers. *Trans R Soc Trop Med Hyg*. 2004;98:12-17.
- 1371 182. Francino O, Altet L, Sanchez-Robert E, et al.: Advantages of real-time PCR assay for
1372 diagnosis and monitoring of canine leishmaniosis. *Vet Parasitol*. 2006;137:214-221.
- 1373 183. Martínez V, Quilez J, Sanchez A, Roura X, Francino O, Altet L. Canine
1374 leishmaniasis: the key points for qPCR result interpretation. *Parasit Vectors*. 2011;4:57.
- 1375 184. Solcà Mda S, Guedes CE, Nascimento EG, et al. Qualitative and quantitative
1376 polymerase chain reaction (PCR) for detection of *Leishmania* in spleen samples from
1377 naturally infected dogs. *Vet Parasitol*. 2012;184:133-140.
- 1378 185. Santos TR, Carreira VS, Ferrari HF, Moreira MA, Luvizotto MC. Comparison of
1379 PCR with stained slides of bone marrow and lymph nodes aspirates with suspect diagnosis
1380 for leishmaniasis. *Acta Trop*. 2014;140:137-140.
- 1381 186. Roura X, Fondevila D, Sanchez A, Ferrer L. Detection of *Leishmania* infection in
1382 paraffin-embedded skin biopsies of dogs using polymerase chain reaction. *J Vet Diagn*
1383 *Invest*. 1999;11:385-387.

- 1384 187. Muller N, Zimmermann V, Forster U, Bienz M, Gottstein B, Welle M. PCR-based
1385 detection of canine *Leishmania* infections in formalin-fixed and paraffinembedded skin
1386 biopsies: elaboration of a protocol for quality assessment of the diagnostic amplification
1387 reaction. *Vet Parasitol.* 2003;114:223-229.
- 1388 188. Gradoni, L. The diagnosis of canine leishmaniasis. In: Killick-Kendrick R, ed.
1389 *Canine leishmaniasis: moving towards a solution. Proceedings of the 2nd International*
1390 *leishmaniasis Forum, Sevilla, Spain.* Boxmeer, NL. Intervet International. 2002:7-14.
- 1391 189. Ramos RA, Ramos CA, Santos EM, et al. Quantification of *Leishmania infantum*
1392 DNA in the bone marrow, lymph node and spleen of dogs. *Rev Bras Parasitol Vet.*
1393 2013;22:346-350.
- 1394 190. Carvalho Ferreira AL, Carregal VM, de Almeida Ferreira S, Leite RS, de Andrade
1395 AS. Detection of *Leishmania infantum* in 4 different dog samples by real-time PCR and
1396 ITS-1 nested PCR. *Diagn Microbiol Infect Dis.* 2014;78:418-421.
- 1397 191. Almeida AB, Sousa VR, Gasparetto ND, et al. Canine visceral leishmaniasis:
1398 diagnostic approaches based on polymerase chain reaction employing different biological
1399 samples. *Diagn Microbiol Infect Dis.* 2013;76:321-324.
- 1400 192. Reis LE, Coura-Vital W, Roatt BM, et al. Molecular diagnosis of canine visceral
1401 leishmaniasis: a comparative study of three methods using skin and spleen from dogs with
1402 natural *Leishmania infantum* infection. *Vet Parasitol.* 2013;197:498-503.
- 1403 193. Ferreira Sde A, Ituassu LT, de Melo MN, de Andrade AS: Evaluation of the
1404 conjunctival swab for canine visceral leishmaniasis diagnosis by PCR-hybridization in
1405 Minas Gerais State, Brazil. *Vet Parasitol.* 2008;152:257-263.
- 1406 194. Gramiccia M, Di Muccio T, Fiorentino E, et al.: Longitudinal study on the detection
1407 of canine *Leishmania* infections by conjunctival swab analysis and correlation with
1408 entomological parameters. *Vet Parasitol.* 2010;171:223-228.

- 1409 195. Di Muccio T, Veronesi F, Antognoni MT, Onofri A, Piergili Fioretti D, Gramiccia
1410 M. Diagnostic value of conjunctival swab sampling associated with nested PCR for different
1411 categories of dogs naturally exposed to *Leishmania infantum* infection. *J Clin Microbiol.*
1412 2012;50:2651-2659.
- 1413 196. Ferreira Sde A, Almeida GG, Silva Sde O, et al. Nasal, oral and ear swabs for canine
1414 visceral leishmaniasis diagnosis: new practical approaches for detection of *Leishmania*
1415 *infantum* DNA. *PLoS Negl Trop Dis.* 2013;7:e2150.
- 1416 197. Madeira MF, Figueiredo FB, Pinto AG, et al.: Parasitological diagnosis of canine
1417 visceral leishmaniasis: is intact skin a good target? *Res Vet Sci.* 2009;87:260-262.
- 1418 198. Diniz SA, Melo MS, Borges AM, et al. Genital lesions associated with visceral
1419 leishmaniasis and shedding of *Leishmania spp.* in the semen of naturally infected dogs. *Vet*
1420 *Pathol.* 2005;42:650-658
- 1421 199. Manna L, Paciello O, Morte RD, Gravino AE. Detection of *Leishmania* parasites in
1422 the testis of a dog affected by orchitis: case report. *Parasit Vectors.* 2012;5:216.
- 1423 200. Levy E, Mylonakis ME, Saridomichelakis MN, Polizopoulou ZS, Psychogios V,
1424 Koutinas AF. Nasal and oral masses in a dog. *Vet Clin Pathol.* 2006;35:115-118
- 1425 201. Caniatti M, da Cunha NP, Avallone G, et al. Diagnostic accuracy of brush cytology
1426 in canine chronic intranasal disease. *Vet Clin Pathol.* 2012;41:133-140.
- 1427 202. Costa MM, Lima WG, Figueiredo MM, Michalick MS, Tafuri WL, Tafuri WL.
1428 Cervical, mandibular, and parotid lymph nodes of dogs naturally infected with *Leishmania*
1429 *infantum*: a histopathologic and immunohistochemistry study and its correlation with facial
1430 skin lesions. *Vet Pathol.* 2008;45:613-616.
- 1431 203. Mylonakis ME, Papaioannou N, Saridomichelakis MN, Koutinas AF, Billinis C,
1432 Kontos VI. Cytologic patterns of lymphadenopathy in dogs infected with *Leishmania*
1433 *infantum*. *Vet Clin Pathol.* 2005;34:243-247.

- 1434 204. Fernandes PJ. Synovial fluid analysis. In: Cowell RL, Tyler RD, Meinkoth JH,
1435 DeNicola DB,eds. *Diagnostic cytology and hematology of the dog and cat*. 3rd ed. St. Louis,
1436 MO: Mosby Elsevier; 2008:193-209.
- 1437 205. Desnoyers M, Bedard C, Meinkoth JH, Crystal MA. Cerebrospinal fluid analysis In:
1438 Cowell RL, Tyler RD, Meinkoth JH, DeNicola DB,eds. *Diagnostic cytology and*
1439 *hematology of the dog and cat*. 3rd ed. St. Louis, MO: Mosby Elsevier; 2008:215-234.
- 1440 206. Ferro S, Palmieri C, Cavicchioli L, De Zan G, Aresu L, Benali SL. *Leishmania*
1441 amastigotes in neoplastic cells of 3 nonhistiocytic canine tumors. *Vet Pathol*. 2013;50:749-
1442 752.
- 1443 207. Kegler K, Habierski A, Hahn K, Amarilla SP, Seehusen F, Baumgärtner W. Vaginal
1444 canine transmissible venereal tumour associated with intra-tumoural *Leishmania spp.*
1445 amastigotes in an asymptomatic female dog. *J Comp Pathol*. 2013;149:156-161.
- 1446 208. Marino G, Gaglio G, Zanghi A. Clinicopathological study of canine transmissible
1447 venereal tumour in leishmaniotic dogs. *J Small Anim Pract*. 2012;53:323-327.
- 1448 209. Foglia Manzillo V, Pagano A, Guglielmino R, Gradoni L, Restucci B, Oliva G.
1449 Extranodal gammadelta-T-cell lymphoma in a dog with leishmaniasis. *Vet Clin Pathol*.
1450 2008;37:298-301.
- 1451 210. Catone G, Marino G, Poglayen G, Gramiccia M, Ludovisi A, Zanghi A. Canine
1452 transmissible venereal tumour parasitized by *Leishmania infantum*. *Vet Res Commun*.
1453 2003;27:549-553.
- 1454 211. Albanese F, Poli A, Millanta F, Abramo F. Primary cutaneous extragenital canine
1455 transmissible venereal tumour with *Leishmania*-laden neoplastic cells: a further suggestion
1456 of histiocytic origin? *Vet Dermatol*. 2002;13:243-246.
- 1457 212. Toplu N, Aydogan A. An immunohistochemical study in cases with usual and
1458 unusual clinicopathological findings of canine visceral leishmaniosis. *Parasitol Res*.
1459 2011;109:1051-1057.

- 1460 213. Menezes RC, Figueiredo FB, Wise AG, et al. Sensitivity and specificity of in situ
1461 hybridization for diagnosis of cutaneous infection by *Leishmania infantum* in dogs. *J Clin*
1462 *Microbiol.* 2013;51:206-211.
- 1463 214. Dinhopl N, Mostegl MM, Richter B, et al. In situ hybridisation for the detection of
1464 *Leishmania* species in paraffin wax-embedded canine tissues using a digoxigenin-labelled
1465 oligonucleotide probe. *Vet Rec.* 2011;169:525.
- 1466 215. Nieto CG, Navarrete I, Habela MA, Serrano F, Redondo E. Pathological changes in
1467 kidneys of dogs with natural *Leishmania* infection. *Vet Parasitol.* 1992;45:33-47.
- 1468 216. Koutinas AF, Carlotti DN, Koutinas C, Papadogiannakis EI, Spanakos GK,
1469 Saridomichelakis MN. Claw histopathology and parasitic load in natural cases of canine
1470 leishmaniosis associated with *Leishmania infantum*. *Vet Dermatol.* 2010;21:572-577
- 1471 217. Naranjo C, Fondevila D, Altet L, et al. Evaluation of the presence of *Leishmania spp.*
1472 by real-time PCR in the lacrimal glands of dogs with leishmaniosis. *Vet J.* 2012;193:168-
1473 173.
- 1474 218. Figueiredo MM, Moura EP, Costa MM, et al. Histopathological and parasitological
1475 investigations of ear healthy skin of dogs naturally and experimentally infected with
1476 *Leishmania (Leishmania) chagasi*. *Histol Histopathol.* 2010;25:877-887.
- 1477 219. Moreira PR, Vieira LM, de Andrade MM, et al. Immune response pattern of the
1478 popliteal lymph nodes of dogs with visceral leishmaniasis. *Parasitol Res.* 2010;107:605-
1479 613.
- 1480 220. Pinto AJ, Figueiredo MM, Silva FL, et al. Histopathological and parasitological
1481 study of the gastrointestinal tract of dogs naturally infected with *Leishmania infantum*. *Acta*
1482 *Vet Scand.* 2011;53:67.
- 1483 221. Bardagi M, Fondevila D, Zanna G, Ferrer L. Histopathological differences between
1484 canine idiopathic sebaceous adenitis and canine leishmaniosis with sebaceous adenitis. *Vet*
1485 *Dermatol.* 2010;21:159-165.

- 1486 222. Bongiorno G, Paparcone R, Foglia Manzillo V, Oliva G, Cuisinier AM, Gradoni L.
1487 Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in
1488 *Phlebotomus perniciosus* fed on *Leishmania infantum* infected dogs--a preliminary
1489 xenodiagnosis study. *Vet Parasitol.* 2013;197:691-695.
- 1490 223. Longoni SS, Sánchez-Moreno M, López JE, Marín C. *Leishmania infantum* secreted
1491 iron superoxide dismutase purification and its application to the diagnosis of canine
1492 Leishmaniasis. *Comp Immunol Microbiol Infect Dis.* 2013;36:499-506.
- 1493 224. Britti D, Gaspari M, Massimini G, Casalnuovo F, Morittu VM, Cuda G. Proteomic
1494 analysis in canine leishmaniasis. *Vet Res Commun.* 2010;34 Suppl 1:S91-596.
- 1495 225. Menezes-Souza D, Corrêa-Oliveira R, Guerra-Sá R, et al. Cytokine and transcription
1496 factor profiles in the skin of dogs naturally infected by *Leishmania (Leishmania) chagasi*
1497 presenting distinct cutaneous parasite density and clinical status. *Vet Parasitol.*
1498 2011;177:39-49.
- 1499 226. Di Loria A, Squillacioti C, De Luca A, et al. Increased leptin mRNA expression in
1500 the blood of dogs naturally infected by *Leishmania infantum*. *Vet J.* 2014;202:634-636.
- 1501 227. dos Santos FR, Vieira PM, Correa-Oliveira R, et al. Qualitative and quantitative
1502 immunohistochemical evaluation of iNOS expression in the spleen of dogs naturally
1503 infected with *Leishmania chagasi*. *Parasitol Res.* 2011;108:1397-1403.
- 1504 228. Melo GD, Marangoni NR, Marcondes M, Lima VM, Machado GF. High levels of
1505 serum matrix metalloproteinases in dogs with natural visceral leishmaniosis: a preliminary
1506 report. *Vet J.* 2011;188:243-245.
- 1507 229. Marangoni NR, Melo GD, Moraes OC, Souza MS, Perri SH, Machado GF. Levels of
1508 matrix metalloproteinase-2 and metalloproteinase-9 in the cerebrospinal fluid of dogs with
1509 visceral leishmaniasis. *Parasite Immunol.* 2011;33:330-334.
- 1510 230. Lugin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress
1511 during inflammatory processes. *Biol Chem.* 2014;395:203-230.

- 1512 231. Heidarpour M, Soltani S, Mohri M, Khoshnegah J. Canine visceral leishmaniasis:
1513 relationships between oxidative stress, liver and kidney variables, trace elements, and
1514 clinical status. *Parasitol Res.* 2012;111:1491-1496.
- 1515 232. Almeida BF, Narciso LG, Melo LM, et al. Leishmaniasis causes oxidative stress and
1516 alteration of oxidative metabolism and viability of neutrophils in dogs. *Vet J.* 2013;198:599-
1517 605.
- 1518 233. Souza CC, Barreto Tde O, da Silva SM, et al. A potential link among antioxidant
1519 enzymes, histopathology and trace elements in canine visceral leishmaniasis. *Int J Exp*
1520 *Pathol.* 2014;95:260-270.
- 1521 234. Paltrinieri S, Ravicini S, Rossi G, Roura X Serum concentration of the derivative of
1522 reactive oxygen metabolites (d-ROMs) in dogs with leishmaniosis. *Vet J.* 2010;186:393-
1523 395.
- 1524 235. Oliva G, Roura X, Crotti A, et al. Guidelines for treatment of leishmaniasis in dogs. *J*
1525 *Am Vet Med Assoc.* 2010;236:1192-1199.
- 1526 236. Bianciardi P, Brovida C, Valente M, et al. Administration of miltefosine and
1527 meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the
1528 kidneys. *Toxicol Pathol.* 2009;37:770-775.
- 1529 237. Miró G, Oliva G, Cruz I, et al. Multicentric, controlled clinical study to evaluate
1530 effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. *Vet*
1531 *Dermatol.* 2009;20:397-404.
- 1532 238. Xenoulis PG, Saridomichelakis MN, Chatzis MK, et al. Prospective evaluation of
1533 serum pancreatic lipase immunoreactivity and troponin I concentrations in *Leishmania*
1534 *infantum*-infected dogs treated with meglumine antimonate. *Vet Parasitol.* 2014;203:326-
1535 330.

- 1536 239. Luciani A, Sconza S, Civitella C, Guglielmini C. Evaluation of the cardiac toxicity of
1537 N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis. *Vet J.*
1538 2013;196:119-121.
- 1539 240. Torres M, Bardagí M, Roura X, Zanna G, Ravera I, Ferrer L. Long term follow-up of
1540 dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine
1541 antimoniate and allopurinol. *Vet J.* 2011;188:346-351.
- 1542 241. Pierantozzi M, Roura X, Paltrinieri S, Poggi M, Zatelli A. Variation of proteinuria in
1543 dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: 53 cases
1544 (2006-2010). *J Am Anim Hosp Assoc.* 2013;49:231-236.
- 1545 242. Roura X, Fondati A, Lubas G, et al. Prognosis and monitoring of leishmaniasis in
1546 dogs: A working group report. *Vet J.* 2013;198:43-47.
- 1547 243. Goldstein RE, Brovida C, Fernández-Del Palacio MJ, et al, Consensus
1548 recommendations for treatment for dogs with serology positive glomerular disease. *J Vet*
1549 *Intern Med.* 2013;27 Suppl 1:S60-6.
- 1550 244. Rossi G, Ibba F, Meazzi S, Giordano A, Paltrinieri S. Paraoxonase activity as a tool
1551 for clinical monitoring of dogs treated for canine leishmaniasis. *Vet J.* 2014;199:143-149.
- 1552 245. Rougier S, Hasseine L, Delaunay P, Michel G, Marty P. One-year clinical and
1553 parasitological follow-up of dogs treated with marbofloxacin for canine leishmaniosis. *Vet*
1554 *Parasitol.* 2012;186:245-253.
- 1555 246. Manna L, Corso R, Galiero G, Cerrone A, Muzj P, Gravino AE. Long-term follow-
1556 up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus
1557 miltefosine plus allopurinol. *Parasit Vectors.* 2015;8:289.
- 1558 247. Morales-Yuste M, Morillas-Márquez F, Díaz-Sáez V, Barón-López S, Acedo-
1559 Sánchez C, Martín-Sánchez J. Epidemiological implications of the use of various methods
1560 for the diagnosis of canine leishmaniasis in dogs with different characteristics and in
1561 differing prevalence scenarios. *Parasitol Res.* 2012;111:155-164.